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ABSTRACT 
 
 
 
 
 
 
 
 
Congenital Hypothyroidism (CH) is the most common congenital endocrine disease that 
can be broadly classified as failure of the gland to develop normally (dysgenesis) or 
inadequate thyroid hormone (TH) production from eutopic thyroid gland 
(dyshormonogenesis). Biochemically, CH patients are characterized by low circulating 
levels of T4 and T3 associated with an increased production of TSH due to the feedback 
mechanisms controlling the hypothalamic-pituitary-thyroid (HPT) axis. 
CH is considered a disease with a strong genetic component, but with a largely missing 
explanation for its heritability. At present, genetic variants in candidate genes explain 
only the 10% of CH cases.   
The extraordinary progresses in high-throughput screening technologies lead to the 
identification of several genes involved in the thyroid development and TH synthesis. 
Recently, the transcription factor GLI-Similar protein 3 (GLIS3) has emerged as a new 
candidate gene for CH, but its role in thyroid development and function remains largely 
unexplored. 
GLIS3 is a member of the Kruppel-like zinc-finger transcription factors that can acts as 
activator or repressor of gene expression. Homozygous and compound heterozygous 
GLIS3 variants have been associated with NDH syndrome, characterized by neonatal 
diabetes (T1D and T2D), CH and polycystic kidney. Additionally, several missense 
heterozygous GLIS3 variants have been also identified in cohorts of patients with 
isolated CH. Interestingly, heterozygous GLIS3 variants are associated with other 
mutations in genes involved in thyroid functioning, supporting the hypothesis of the 
oligogenic CH origin. 
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In both NDH and isolated CH patients, the thyroid disease is extremely heterogeneous. 
In fact, most of the affected cases present variable thyroid dysgenesis (athyreosis, 
thyroid hypoplasia and ectopy), whereas dyshormonogenesis with eutopic in situ gland 
is also reported.  
Evidences from Glis3 knockout mice indicate a relevant role of Glis3 in TH 
biosynthesis and postnatal follicle proliferation, with a mechanism of action 
downstream of the TSH/TSHR signalling and thyroid cell proliferation. However, no 
significant thyroid developmental defects were observed in this particular mice model. 
Since GLIS3 mutations are variably associated with thyroid dysgenesis, the aim of this 
study is to gain insight on GLIS3 activity during the early steps of thyroid development, 
using zebrafish as a model system.  
 
In zebrafish (zf), we observed the expression of glis3 transcript from the early 
developmental stages onwards, with a particularly evident signal at 1 dpf (day post 
fertilization) in the pharyngeal endoderm, the embryonic tissue that will give rise to 
endocrine organs, like thyroid and pancreas, and in the pronephric ducts. In apparent 
contrast with mouse data, glis3 is absent in the differentiated thyrocytes of zebrafish 
embryos at 2-3 dpf.  
Transient knockdown zebrafish embryos (called glis3_MOs), obtained by the 
microinjection of specific glis3 morpholinos, revealed a reduced expression of the early 
thyroid markers nkx2.4, and pax2a, at 1dpf. The defective specification of the thyroid 
primordium at this early developmental stage was not associated with reduced 
proliferation or increased apoptosis of thyroid precursors, thus indicating that this 
phenotype was likely due to alterations in the commitment of endodermal cells toward 
the thyroid fate. Such defect resulted in a reduction in size of the differentiated thyroid 
precursors with a diminished expression of both tg and slc5a5, and later on in the 
number of functional thyroid follicles. At 5dpf, the stage in which the thyroid gland is 
functional and responds to the HPT-axis, decreased levels of T4 associated with tshba 
elevation were also seen in glis3_MOs. The specificity of the thyroid defects was 
confirmed by the rescue phenotype after co-injection of the wild-type zf-glis3 transcript 
(WT mRNA) and the glis3 morpholino. In contrast with morpholino knock-down, the 
overexpression of the glis3 mRNA leads to an increase of the number of the thyroid 
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precursors at 1dpf, thus leading to the differentiation of a larger thyroid tissue and an 
elevation of T4 levels at 5 dpf. Taken together, our results demonstrate that glis3 acts at 
the endodermal level controlling the commitment of endocrine precursors, potentially 
representing a required factor for the early specification of thyroid primordium.  
Given the current knowledge, GLIS3 is reported to interact with a pivotal element 
within the Sonic hedgehog (Shh) pathway. Previous experiments in the mouse model 
indicated a potential role for such pathway in thyroid development, but the underlying 
mechanisms and the stage of Shh action in this context are still elusive. Our experiments 
revealed that the expression of shha (the zf homologous of human Shh) was 
significantly reduced in the pharyngeal endoderm of glis3_MOs. Consistently, the 
injection of a morpholino against shha abolished the expression of glis3 in the 
endodermal layer, as well as the treatment with Cyclopamine (a Shh-antagonist) caused 
a reduced or absent expression of glis3, thus confirming the co-involvement of shha and 
glis3 during the thyroid cell specification. Interestingly enough, the overexpression of 
glis3 mRNA failed to rescue the thyroid defects in the Cyclopamine-treated embryos, 
suggesting that glis3 would act as downstream effector of the Shh pathway. 
In conclusion, this is the first evidence of the possible interaction between Shh and 
Glis3 during the early specification of thyroid primordium. Since the mechanisms 
involved in such a delicate event are largely unknown, our data provide important 
insights as glis3 appears as an endoderm factor required for the commitment of 
endoderm cells toward the thyroid fate. These data shed new light into the molecular 
mechanisms potentially involved in CH pathogenesis. 
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INTRODUCTION 
 
 
 
 
 
 
 
I.  THE THYROID GLAND:  AN OVERVIEW 
 
The thyroid gland, through the production of the thyroid hormones (TH), including 
thyroxine (T4) and the bioactive form triiodothyronine (T3), plays multiple roles during 
the embryonic development of several organs and regulates the homeostasis of several 
physiological mechanisms, including body growth and metabolism postnatally [1, 2].  
In vertebrates, the thyroid is a gland composed by two lobes connected by an isthmus 
located adjacent to the trachea (Figure 1A).  
The gland is composed by the fusion of primordial tissues that develop from the anterior 
foregut: the thyroid diverticulum that derived from the endoderm, and the 
ultimobranchial bodies, a bilateral structures that give rise form the neural crests. The 
diverticulum originates form the midline anlage located in the pharyngeal floor, which 
enclose a small group of endodermal cells, which will form the thyroid follicular cells 
[2]. The ultimobranchial bodies (UBB) are transient embryonic structures, located on 
the sides of the developing neck, containing the parafollicular calcitonin producing cells 
(C-cells). 
During embryogenesis, the cells of the thyroid anlage and the UBB migrate and merge 
to form the definitive thyroid gland that is visible as a compact organ, in which the 
endoderm-derived cells organize the TH-producing thyroid follicles, whereas the C-
cells are dispersed in the interfollicular space (Figure 1B). A rich network of capillaries 
surrounds the thyroid follicles providing the systemic delivery of released TH. Finally, 
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the stromal compartment, which encapsulates and separates the follicular thyroid tissue, 
consists mainly of ectomesenchymal fibroblast derived from the neural crest [2].  
 
 
  
 
Figure 1. Thryoid gland anatomy. a) Gross anatomy, anterior view; b) Histology, showing the thyroid 
follicles formed by follicular cells and colloid, and nest of C-cells.   
 
The thyroid follicular cell (or thyrocyte) is the functional unit of the gland, and is 
composed by a monolayer of cuboidal-epithelial cells that encloses a central lumen 
filled with colloid, a proteinaceous depot of TH precursors [2]. The thyroid epithelium 
is morphologically and functionally polarized, with the apical surface facing the colloid 
and a basolateral surface facing the interstitium (Figure 2a). Iodination and TH 
synthesis occur in the colloid at the apical plasma membrane. TH production starts with 
the synthesis of thyroglobulin (TG) that is secreted into the colloid of the thyroid 
follicles by exocytosis. Meanwhile, a sodium-iodide symporter (NIS or SLC5A5) 
pumps iodide actively into the cell and enters the follicular lumen from the cytoplasm 
by the transporter pendrin (SLC26A4) (Figure 2b). In the colloid, iodide is oxidized to 
iodine by thyroid peroxidase (TPO) and iodinate the TG at the level of the tyrosyl-
residues to produce thyroxine (T4) and triiodothyronine (T3) (Figure 2c). TG re-enters 
the follicular cells by endocytosis and TH are liberated by proteolysis, whereas TG is 
degraded via lysosomes (Figure 2d). The efflux of TH into the bloodstream appears 
largely through the monocarboxylate transporters (MCT) 8 and 10 (Figure 2e) [2]. 
 
Thyroid follicle 
Colloid 
C-cell 
Follicular cell 
a.# b.#
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Figure 2. Synthesis of TH in the thyrocyte. (a) View of thyroid follicle structure; (b) Import of iodide 
into colloid; (c) Synthesis of TG and exocytosis into the lumen; (d) Iodination of the tyrosine residues of 
the TG; (e) Conjugation of the iodinated residues and endocytosis into the follicular cell; (f) Proteolysis 
of conjugated-TG and release of TH into the blood by specific transporters (MCT) [Modified from 
(Mikael 2014)]. 
	
	
	
The proper amount of TH is finely regulated by the removal of an atom of iodine form 
specific tyrosine residues. Most of the T3 is produced in the liver (in mammals) or the 
kidney (in fish), by outer ring deiodination (ORD) of T4 operated largely by the type-2 
deiodinase (DIO2) enzyme, and to a lesser extent by the DIO1. Both T4 and T3 are 
inactivated by the inner ring deiodination (IRD) of DIO3 that produce reverse T3 (rT3) 
and T2, respectively. The T3 re-enters the bloodstream to reach the rest of the body 
(Figure 3).  
 
 
b"
c"
e"
d"
f"
a"
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Figure 3. Metabolism of TH. T4 is converted to T3 by the DIO2 and DIO1. DIO3 produces the rT3 and 
T2, by the deiodination of T4 and T3, respectively. Modified from Williams and Bassett, 2011 [3]. 
 
 
Once reached the target cell, T3 is actively transported into the nucleus where it binds 
specific thyroid hormone receptors (TRs) [4]. TRs, including the TRα1, TRβ1 and 
TRβ2 isoforms, function as homodimers or heterodimers with the retinoic acid receptor 
(RXR) recognizing specific sequences (thyroid responsive elements, TREs) located in 
the promoter of target genes [5, 6]. In the absence of T3, TRs repress basal transcription 
through association with a variety of corepressors that limits the access of the basal 
transcriptional machinery. The binding of T3 induces structural changes that release the 
corepressors and recruit coactivators, that facilitate transcription [7]. Depending on the 
type of TRE, the TRs can positively or negatively regulate gene expression (Figure 4). 
Circulating TH levels are maintained within a narrow range by the control of the 
hypothalamic-pituitary-thyroid (HPT) axis. Low levels of T3 trigger the release of the 
thyrotropin-releasing hormone (TRH) from the hypothalamus that in turn stimulates the 
anterior pituitary to secrete the thyroid-stimulating hormone (TSH). The TSH binds the 
TSH-receptor (TSHR) expressed on the basolateral membrane of the thyrocytes and 
thus activating the biosynthesis of TH. By negative feedback inhibition, elevated levels 
of T3 repress the release of both TRH and TSH [8, 9].  (Figure 5). 
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Figure 4. TH action. In this illustration, T3 binds complex formed by TR, RXR and the positive TRE. 
The activation of the transcriptional machinery activates gene expression. Figure modified from [8, 9] 
 
 
 
Figure 5. Control of TH secretion. Low T3 levels trigger the synthesis of hypothalamic TRH and the 
pituitary TSH that stimulate the production of TH. Conversely, high T3 levels produce opposite effects 
[8, 9]. 
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II.  THYROID MORPHOGENESIS:  A MULTISTEP PROCESS 
 
The formation of the three primary germ layers (ectoderm, mesoderm and endoderm) 
takes place during early gastrulation of the vertebrate embryo. The inner layer, 
endoderm, contributes to organize the digestive tract, the associated organs: liver, 
pancreas, lung and thyroid. The precise control of endoderm patterning is required for 
proper organogenesis [11-13]. 
During development, the thyroid gland undergoes a series of morphological changes, 
which are promoted by the expression of specific transcription factors [4, 15].  
The multistep process of thyroid organogenesis, can be summarised as follow (Figure 
6):   
1) Formation of the thyroid placode through the assembling of the thyroid 
progenitors in the pharyngeal floor of the endoderm, upon the aortic sac. At the 
molecular level, these cells can be distinguished by the combined expression of 
NKX2-1, PAX8, HHEX and FOXE1. These transcription factors play a 
fundamental role not only in the formation of the thyroid bud, but also in the 
functional differentiation of the gland in late development and postnatally [4, 
15]. 
2) The growing placode evaginates to form the thyroid bud. 
3) Caudal migration of the thyroid placode along the anterior neck region, taking 
contact with the surrounded mesenchyme.  
4) Bifurcation of the thyroid primordium that extends bilaterally along the 
pharyngeal arch arteries. 
5) Bilobation, involving the fusion of the thyroid primordium with the 
ultimobranchial bodies (UBBs). An isthmus connects the two lobes.   
6) Folliculogenesis, the last morphogenic step during which the follicles are 
functionally differentiated, and are surrounded by the C cells.  
 
By this process, the final shape of the gland is established, and the thyrocytes start to 
express genes involved in iodine uptake and TH synthesis, such as the sodium-iodine 
symporter (NIS or SLC5A5), thyroglobulin (TG) and thyreoperoxidase (TPO).  
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In mice, the entire process takes place in one week, from E8.5 to E15.5, whereas in 
humans, the thyroid development occurs during the E20 to the E70 [2, 10].  
Although the gland is completely formed, the embryo is still dependent by the maternal 
supply of TH. In fact, as evidenced by genetic deletion experiments, the thyroid-
stimulating hormone (TSH), the fine regulator of thyroid function, does not participate 
in the early embryonic morphogenesis and growth of the gland. In mice this occur 
postnatally whereas in humans TSH regulates fetal thyroid growth in the third trimester 
[15]. 
 
 
Figure 6. Morphogenesis of the thyroid gland. (1) Assembly of endoderm-derived thyroid progenitors 
to form the thyroid placode (p), above the aortic sac (as); (2) Emergence of the thyroid bud (b); (3) 
Migration of the thyroid primordium leaving the foramen caecum (fc), transiently connecting the 
thyroglossal duct (td) and reaching the final destination with the surrounding mesenchyme (m); (4) 
Bifurcation of the primordium that extends bilaterally along the pharyngeal arch arteries (aap); (5) 
Bilobation involving the fusion of the primordium with the UBBs. Right and left lobe are connected by an 
isthmus (i); (6) Lobe growth, migration of the C-cells (c) and differentiation of thyroid follicles (f). Figure 
modified from Nilsson and Fagman, 2017 [2].  
NKX2%1'
PAX8'
HHEX'
FOXE1'
TG'
SLC5A5'
TPO'
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A.   Zebrafish thyroid gland: similarities and differences 
 
With regard to zebrafish, the ontogeny of the thyroid follows the same pattern in all 
vertebrates and zebrafish, as previously described: the thyroid anlage always origins in 
the primitive pharynx and thyroid follicular cells migrate from the anlage to reach their 
definitive position and finally organize themselves into follicles in a specie-specific 
manner. Moreover, the expression of a conserved thyroid transcription factor network 
has been demonstrated in the developing thyroid of zebrafish (Figure 7).  
However, differences exist in in the anatomy of mature thyroid tissue and in the timing 
of specific morphogenetic events [11, 12]. The zebrafish thyroid completes its 
development without assuming a glandular organization, with raw of non-encapsulated 
thyroid follicles that are scattered between the first gill arch and the bulbus arteriosus 
within the sub-pharyngeal mesenchyme, along the ventral aorta (Figure 7). Moreover, 
the UBBs and the derived-C cells remain separated from the rest of the thyroid. In 
zebrafish, the onset of folliculogenesis takes place earlier than in mammals (T4 
production assessed from 55 hours post-fertilization, hpf) [13, 14], and the final 
expansion of thyrocytes are TSH-dependent by 100hpf [15]. This is probably due to the 
fact that zebrafish embryos demand to become independent from maternal TH supply 
already in early development [13].  
 
 
Figure 7. Events of the zebrafish thyroid development. The time to each step with the relative 
expression of early and late genes are reported as hpf (hours post-fertilization) [2, 16, 17]. 
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III.  GENETIC REGULATION OF THYROID DEVELOPMENT  
 
In this section we report the current knowledge about the genetic factors involved in 
thyroid organogenesis. 
As mentioned above, a set of genes, unique to the thyroid follicular cell type, has been 
identified as responsible for driving thyroid specific gene expression. It comprises the 
transcription factors NKX2-1, PAX8, HHEX and FOXE1, each of them is also expressed 
in different cell types. However, the combination of these factors to the thyroid 
primordium can be considered as a thyroid signature within the anterior foregut 
endoderm [18].  
 
§ NKX2-1 
NKX2-1, primarily known as thyroid transcription factor-1 (TTF-1), is one of the main 
actors during the organogenesis from the pharyngeal endoderm [2]. NKX2-1 is a 
member of the homeodomain transcription factor family, expressed in thyroid, lung and 
ventral forebrain of higher vertebrates [19]. It was identified as a nuclear protein able to 
recognise and bind specific DNA sequence on the thyroglobulin promoter [20].   
As mentioned before, NKX2-1 is expressed early during the specification of the thyroid 
placode where contributes to the specification and differentiation of the thyroid follicles 
[19]. Nkx2-1 knockout (KO) mice present athyreosis and arrest the lung development at 
the early developmental stages [21]. Further investigations defined that in this mice the 
thyroid rudiment is initially formed but then it disappears through apoptosis [18, 21]. 
These results demonstrate that Nkx2.1 is not required for the initial specification of 
thyroid, but is fundamental for the survival of the thyroid cells precursors, also 
controlling the expression of genes involved in thyrocyte differentiation, like 
thyroglobulin [2, 20].  
In zebrafish, the transient KO of nkx2.4 (homologous of the mammalian NKX2-1) by 
morpholino microinjection leads to defects in thyroid morphogenesis resulting in 
athyreosis, as confirmed by the absence of T4-producing follicle at 5dpf. Similarly, 
nkx2.4 KO displays complete absence of the thyroid or severe thyroid hypoplasia at 
55hpf [22]. Taken together, these data suggest that NKX2-1 exhibits an evolutionary 
conserved role in regulating thyroid development.  
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§ PAX8 
PAX8 (paired box-8) gene is detectable only in the thyroid endoderm derived-organs [2] 
and, like NKX2-1, starts to be expressed in the thyroid primordium and it is maintained 
in the thyroid follicular cells during all stages of development and in adulthood [20].  
In the Pax8-/- mice the thyroid gland is severely affected, thyroid follicles are 
undetectable and C cells mostly compose the gland. KO mice died early after weaving 
due to the severity of the hypothyroidism that can be rescued by T4 administration [23, 
24]. Further analysis confirmed that Pax8 is required for the survival of the thyroid 
precursors rather than in thyroid differentiation. Moreover, it has been demonstrated 
that Pax8 directly regulates the expression of the other early thyroid genes. In fact, in 
Pax8 KO mice, the expression Hhex and Foxe1 are strongly down-regulated [20].  
In zebrafish, two pax genes (pax2a and pax8) are expressed in thyroid primordium at 
24hpf. Zebrafish noi mutants (deficient in pax2a activity) develop the thyroid 
primordium and express nkx2.4 and hhex until 30hpf, but no active follicles are 
detectable at 5dpf	 [11]. Phenocopying the thyroid phenotype of noi mutants, in the 
pax2a KO the thyroid anlage is formed, but the expression of thyroid markers becomes 
severely impaired or is absent [22]. The finding that the phenotypes of noi and pax2a 
mutants are similar to that of Pax8 KO mice, suggests that zebrafish pax2a, acting 
upstream of pax8, plays a similar role in thyroid development [25].   
In both mice and zebrafish, the anti-apoptotic factor Bcl2 strongly accumulates 
specifically in the thyroid bud, suggesting that anti-apoptotic signals are important in 
early thyroid development and that the mechanism is evolutionarily conserved [17, 26]. 
 
§ HHEX 
The haematopoietically homeobox transcription factor HHEX is a critical regulator of 
many aspects of vertebrate development, such as the formation of endoderm-derived 
organs: thyroid, pancreas, liver, lung and thymus [2, 27, 28]. Hhex-null mice display 
aplastic or hypoplastic at E10.5 and complete athyreosis at E13.5, suggesting a very 
early function of Hhex in thyroid development [18]. In zebrafish, the orthologous gene 
hhex is initially expressed in the anterior endoderm, co-localizing with nkx2.1 in the 
thyroid primordium at 22hpf. Morpholino injected embryos result in a lack of T4-
producing follicles at 5dpf whereas the evagination and localization of thyroid 
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primordium are not affected but the expression of nkx2.1 and pax2a is lost at 60hpf. 
Furthermore, the overexpression of hhex increases the number of thyroid precursor cells 
in zebrafish. All together, these studies in zebrafish and mice emphasize the role that 
HHEX gene plays after induction and evagination of the thyroid primordium, when it 
appears to control thyroid differentiation and, perhaps, growth. 
 
§ FOXE1 
FOXE1, previously known as thyroid transcription factor-2 (TTF-2) is identified as a 
nuclear protein able to bind at the thyroglobulin and thyroid peroxidase promoters under 
hormone stimulation [20, 29].  
Like the other thyroid transcription factors, FOXE1 is expressed in the pharyngeal 
endoderm promoting the migration of thyroid precursors [20]. In Foxe1 KO mice the 
thyroid bud is missing or remains a part of the pharyngeal endoderm, demonstrating that 
this factor has an important role during the thyroid primordium migration [30]. Further 
investigations described the importance of Foxe1 in the maintenance of epithelial-
phenotype of progenitor cells during migration and also as a promoter of cell survival, 
probably acting downstream of Pax8. 
Although foxe1 is expressed in thyroid primordium of zebrafish embryos at 24hpf, the 
knockdown of foxe1 have no effects on thyroid morphogenesis. These authors argued 
that the zebrafish thyroid develops very early during development and foxe1’s role 
might be redundant in this context; it is thus possible that the role of FOXE1 in 
mammalian thyroid development may have been acquired during evolution [13, 31].  
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IV.  INTERACTION BETWEEN ENDODERM AND MESODERM     
      DURING THYROID DEVELOPMENT 
 
The specification of the gut region and the derived organs also depends on the crosstalk 
between the endoderm and the mesoderm. Several studies highlight the importance of 
permissive signals sent from the mesoderm layer to promote endoderm organogenesis 
(i.e. during liver and pancreas development) [32-36]. A wide range of intrinsic or 
extrinsic pathways derived from the endoderm and/or the mesoderm has been described 
to contribute to thyroid development [37]. Each gene acts both individually and in 
concert to form a complex network that is required for the proper specification of 
endodermal cells into thyroid precursors, in the migration of thyroid primordium, as 
well as in the correct differentiation and expansion of the gland.   
 
A.    Nodal pathway 
 
During embryogenesis, the Nodal pathway is involved in the definition of mesoderm 
and endoderm from a common territory, the so called mesendodermal layer, as well as 
in positioning of the anterior–posterior axis, neural patterning and left–right axis 
specification [38]. The Nodal gene encodes an activin-like member of the transforming 
growth factor β (TGFβ), and it belonging a complex cascade of signals, it is involved in 
the activation of the transcription of the endoderm-specific genes, like gata5, sox17 and 
foxa2 [39-41]. Much of the role of Nodal signalling in thyroid has been elucidated in the 
zebrafish model. In the Nodal co-receptor one-eyed pinhead mutants (oep-/-), the loss of 
endoderm is evident during gastrulation, with an overall failure in the mesodermal cells 
specification, leading to the absence of thyroid primordium [42]. Furthermore, zebrafish 
mutants in the downstream effectors of Nodal signalling like bon, gata5 and sox32 
completely fail to develop the thyroid primordium, as a consequence of altered 
endoderm organization and of the loss of the direct inductive role that these factors play 
in specifying the thyroid primordium [42-44]. 
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B.    Notch pathway 
 
Notch is a high conserved, local cell-signalling mechanism that participates in a variety 
of cellular processes and it is involved in many aspects of development and disease. 
Notch signalling governs cell fate differentiation and critical cell fate decisions during 
development, the segmentation in lower organism, somitogenesis, neurogenesis, 
vasculogenesis and cardiogenesis [45, 46]. In mammals there are four Notch receptors 
(NOTCH1-4). The receptors interact with different ligands, belonging to Delta- like 
(DLL1-3) and Jagged families (JAG1 and JAG2). Notch binding to ligand elicits several 
steps cleavage that culminates in the releasing of the Notch intracellular domain 
(NICD). NCID translocates into the nucleus, where it induces the expression of several 
genes [47]. Mice KO for the Notch effector Hes1 show thyroid hypoplasia and 
diminished T4 production. Jag1 KO mice present vascular defects that result in 
embryonic lethality before E11.5, precluding the study of thyroid development. 
However, the double heterozygous Jag1/Notch2 mice strongly resemble those seen in 
patients with Alagille syndrome, which includes congenital hypothyroidism as a clinical 
feature [47, 48].  
Studies conducted in zebrafish have shown that the Notch signalling is involved in the 
development of the thyroid gland. Perturbations of the Notch signalling are associated 
with increased (Notch silencing) or diminished (Notch over-activation) number of 
thyroid precursors committed to the thyroid fate. Furthermore, both jag1a and jag1b 
ligands (homologous of the human JAG1) co-localize with tg and play distinct roles 
during thyroid development. Jag1a appear to be important at 72hpf contributing to 
define the number of cells able to proliferate and move caudally to generate new 
follicles, whereas jag1b are involved earlier during the differentiation of the thyroid 
primordium (24-48hpf) [47].  
Taken together these findings indicate a dual role of Notch signalling during zebrafish 
thyroid development: induction of thyroid primordium, restricting the number of 
endodermal cells that will differentiate to thyroid cells, and Jag1-dependent controls of 
differentiation and expansion of thyroid follicles [47]. However, since the Notch 
signalling is expressed in both endoderm and mesoderm, it is possible that permissive 
factors from the surrounding tissues (e.g. lateral plate mesoderm) contribute to the 
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observed phenotype. In fact, the cardiac plate mesoderm is known to be an important 
source of FGF signals that influence thyroid organogenesis, both in zebrafish and mouse 
mode. This support the existence of a common pathway regulating thyroid and heart 
development, and it can also explains the frequent association of cardiac defects in 
patients with thyroid dysgenesis carrying mutations in the JAG1 gene [47, 49]. 
 
 
C.    Sonic Hedgehog pathway 
 
The Sonic Hedgehog (SHH) signalling is involved in several key events during 
embryogenesis of vertebrates, including left–right axis determination and organ 
development [50, 51] and it is also an important regulator of pharyngeal region 
development [52]. Upon secretion, SHH inactivate the transmembrane receptor 
Patched1 (PTCH1), which normally inhibits the activity of the transmembrane protein 
Smoothened (SMO), and resulting in the nuclear localization of glioma-associated 
(GLI) transcription factors, which are the terminal effectors of SHH signalling. It has 
also been described that, in absence of SHH, the Suppressor of Fused (SUFU) 
negatively regulates the pathway by directly binding to GLI and anchoring them in the 
cytoplasm, thus preventing the activation of GLI-target genes (Figure 8). SUFU has also 
been shown to form a repressor complex with GLI1, which translocate into the nucleus 
where it repress gene transcription [53].  
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Figure 8. Sonic Hedgehog signalling. In absence of ligand, the transmembrane receptor SMO is 
maintained inactive by the binding with PTCH1. At the same time, the SUFU anchoring and inhibiting 
GLI activity, When SHH bind PTCH1, SMO is activated and release the inhibition mediated by SUFU, 
allowing the nuclear translocation of GLI and the activation of gene transcription [53]. 
 
 
In Shh KO mice, the thyroid primordium is correctly specified in the pharyngeal 
endoderm, but the thyroid fails to bifurcate developing a single unilateral gland, likely 
due to defective formation of pharyngeal arteries [54]. Defective activity of Shh and its 
receptor Patched both in thyroid and vessel wall strongly suggests that this phenotype 
primarily depends on defective Shh-signalling from the pharyngeal endoderm or loss of 
Shh response in other embryonic tissues that indirectly influence thyroid development 
[52]. However, in mice deficient for Tbx1, a mesodermal target of the Shh signalling, 
the number of cells in the thyroid placode is reduced, the thyroid budding is delayed and 
the thyroid primordium fails to migrate and takes contact with the aortic sac [55].  
In zebrafish, the genes of shh-pathway are expressed in the pharyngeal endoderm at 
early developmental stages [56]. Three-dimensional reconstruction of zebrafish shh 
mutant embryos and rescue experiments shows that the thyroid primordium, after 
normal evagination, fails to bifurcate and is mislocated due to the asymmetrical 
development of pharyngeal arteries [42, 56].  
These results suggest that SHH contributes though the definition of the foregut territory 
for thyroid specification, regulating thyroid migration and bifurcation during the later 
phases of thyroid development [54]. 
SHH OFF SHH ON 
SMO SMO PTCH1 PTCH1 
SHH 
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V.  CONGENITAL HYPOTHYROIDISM (CH) 
 
Primary Congenital Hypothyroidism (CH) is the most common endocrine disease that 
can be broadly classified as failure of the gland to develop normally (dysgenesis) or 
inadequate hormone production from eutopic thyroid gland (dyshormonogenesis). 
Biochemically, CH patients are characterized by low circulating levels of T4 and T3 
associated with an increased production of TSH due to the positive activation of the 
HPT axis. Clinically, the reduced action of TH in the peripheral tissues results in a wide 
spectrum of manifestations, including delayed bone development, mental retardation 
and altered metabolism. The implementation of universal newborns TSH-screening in 
the ‘70s and the timely treatment with L-thyroxine, virtually eradicated significant 
intellectual disabilities due to severe CH [57]. More recently, the increased of stringent 
screening strategies allows the detection of milder cases, and resulting in a dramatic 
increased of the incidence of CH from 1:4000 to 1:2000 over the last years [58]. Several 
concomitant factors (eg, improved outcome of CH more frequently allowing 
transmission of heritable defects, endocrine disrupting chemicals) can contribute this 
phenomenon, but the lower threshold of neonatal TSH screening represents the main 
cause of the increased CH detection [57]. CH has been considered a disease with a 
strong genetic component, but with a largely missing explanation for its heritability.  
Thyroid dysgenesis (TD), which includes thyroid agenesis, hypoplasia, and ectopy, 
occurs in about 80% of CH cases, and its incidence (1:4000) has not significantly 
changes over the past decades. The underlying causes of TD, however, remains obscure 
in the vast majority if cases, with only 2-5% of cases being attributable to genetic 
mutations [20, 59]. Nevertheless, the known genetic causes of TD provide an important 
window into basic thyroid ontogeny (Figure 9).  
Inactivating mutations that contribute to thyroid dysgenesis have been identified in 
genes expressed in thyroid tissues during embryogenesis and in the normal functioning 
thyroid gland (e.g. NKX2-1, NKX2-5, TSHR, PAX8, FOXE1), resulting in a miss-
specification or dislocation of thyroid follicular cells [60]. Since the expression of the 
transcription factors is not restricted to the thyroid, CH is frequently associated to 
additional syndromic features, such as interstitial lung disease and chorea (NKX2-1), 
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and renal abnormalities (PAX8), cleft palate, bifid epiglottis, choanal atresia, and spiky 
hair (FOXE1).    
Unlike TD, the incidence of dyshormonogenesis has been increased of 15-20% in the 
last years. Known genetic causes of dyshormonogenesis are reported in Figure 9 [58, 
61].  
 
 
Figure 9. Genetic causes of CH. Modified from [62]. 
 
Despite the growing number of genes associated with CH, the precise portion that can 
be attributed to mono- or polygenic causes, can explain only the 10% of affected cases. 
The influence of non-genetic factors, such as epigenetics variations and the exposure of 
endocrine disruptors, may contribute to the aetiology of CH. However, further work is 
needed to identify the entire causative factors underlie the multifactorial and polygenic 
origin of CH [57, 63]. Nonetheless, recent studies examining larger sets of candidate 
genes, using next-generation techniques, identified causative variants in a higher portion 
of patients than older studies. For instance, a recent analysis, conducts by our group, of 
11 genes in 177 Italian CH patients demonstrates a prevalence of mutation in 58% of 
cases that is even higher (75%) in patients with eutopic gland. The 23% of cases 
harboured variants in more than one gene, similar to other reports [62, 63]. These results 
Thyroid dysgenesis Dyshormonogenesis 
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suggest that the apparent low heritability of CH may be explained by the confluence of 
rare variants in several genes. Furthermore, in this study, variants in genes typically 
associated with TD (eg. NKX-2-1, FOXE1) has been identified in patients with 
dyshormonogenesis, and vice versa. This finding suggests a crossover in the 
ethiopathogenesis between TD and dyshormonogenesis. 
An example of this potential phenotypic overlap is JAG1, the ligand of the Notch 
pathway that is critical for thyroid development in zebrafish [47].  Heterozygous JAG1 
variants have been described in cohorts of patients with Alagille syndrome 
(mutisystemic disorder) and non-syndromic CH. Interestingly, the thyroid phenotype of 
patients with JAG1 variants included not only TD, as to be expected from the zebrafish 
model, but also dyshormonogenesis. Taken together, the current knowledge highlighted 
the complexity of thyroid development and function and that the genetic component 
underlying the different manifestations of CH may overlap.  
 
 
VI.  THE TRANSCRIPTION FACTOR GLI-SIMILAR 3  (GLIS3)   
 
The transcription factor Gli-similar 3 (GLIS3) belongs to the family of the Krüppel-like 
zinc finger transcription factor [61] and it is involved in several cellular processes, 
including proliferation, apoptosis, differentiation and development [64].  
The human GLIS3 gene is located on chromosome 9p24.2 and encodes a full-length 
protein of 90 kD in size. GLIS3 in expressed in a tissue-specific manner, with highest 
levels in kidney, thyroid gland, endocrine pancreas, thymus, testis and uterus. Lower 
levels of expression have also been reported in brain, lung, ovary and liver [61, 65].  
The GLIS3 protein consists of a centrally located zinc finger domain (ZFD) (five 
tandems Cys2-His2 zinc finger motifs), a C-terminal transactivation domain (TAD) and a 
relatively large N-terminus that is important in the regulation of GLIS3 stability and its 
transcriptional activity [61, 66] (Figure 10). The five Cys2/His2 zinc finger domain 
(ZFD) dictates GLIS3 cytosolic or nuclear localization and it is responsible for the 
recognition of specific DNA responsive elements, the GlisBS (Glis3-binding site, 5-
(G/C)TGGGGGGT(A/C)) localized within the regulatory regions of target genes [64].  
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Figure 10. Schematic structure of GLIS3. The SUFU-interaction motif VYGHF within the N-terminus, 
the zinc finger domain (ZFD) and the C-terminal transactivating domain (TAD) are along the Glis3 
protein structure. The illustration of the Cys2/His2 zinc finger is indicated by the dotted lines. Below is 
reported the positive or negative regulation of Ins2 expression, dictates by the interaction with co-
activators (green box) or co-repressor (red box). Modified from [67]. 
 
 
Several alternate transcripts of GLIS3 have been reported so far in humans. Senee et al. 
established the gene structure of GLIS3 and characterized the alternative transcripts and 
the predicted protein products. Twenty-five putative transcription start sites located in 
12 exons and four transcription termination sites located in four exons have been 
identified. The predicted translation products of these transcripts encode nine variants of 
the GLIS3 protein, most containing the five intact zinc finger domains, with variations 
in the N- and C- terminal regions that might affect the function of the encoded proteins. 
Some transcripts have limited or no coding capacity and may have regulatory function 
[65]. The larger transcript (7.5kb) is predominantly expressed in pancreas, thyroid, and 
kidney, whereas the smaller isoforms (0.8-2kb) are mainly localized in heart, kidney, 
liver and skeletal muscle [68]. Despite the distinct pattern of expression, the 
pathophysiological functions of the variable-length isoforms remain unknown.  
The role of N- and C-terminus of GLIS3 has been determined by the comparison of the 
activity between the full-length and truncated constructs. The deletion of the first 254 
residues in the N-terminus results in a significant increment of transcriptional activity, 
whereas the truncation of 306 residues abolishes such activity [64,63]. Moreover, 
truncations in the C-terminal domain always diminished the activity of GLIS3 [64]. 
Co#repressor(binding((
(SUFU)(
Co#ac5vator(binding((
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 Introduction 
	
30
These data suggests that different regions within the N- and C-terminuses contribute to 
its transcriptional activity.  
Once bound to the DNA, GLIS3 can interact with co-activators or co-repressors, thus 
enhancing or silencing the expression of several target genes [69]. For instance, it has 
been reported that Glis3 has a dual role in controlling the transcription of the Ins2 gene 
(Figure 10). Glis3 directly binds the Glis3-BS localized in the promoter of Ins2 and 
interact with the co-activators MafA and Pdx1 to activate Ins2 expression [70]. On the 
other hand, Glis3 can also bind the co-repressor suppressor of fused (SUFU) through 
the conserved motif VYGHF [71] (Figure 10). This complex is able to translocate into 
the nucleus where it suppresses the expression of Ins2 [67]. SUFU is a negative 
regulator of the Sonic Hedgehog (SHH)/GLI signalling, implicated in several 
developmental processes and tumorigenesis (see Section IV-C for details) [69, 72]. 
However, the precise function of SUFU in GLIS3-mediated transcriptional regulation is 
not fully clarified [69, 71]. 
SUFU plays also an essential role in protecting the degradation of GLIS3. In fact, it has 
been reported that N-terminus of GLIS3 interacts with cullin-RING ubiquitin ligase 3 
(CUL3) and with the ubiquitin ligase ITCH, promoting the poly-ubiquitination and the 
degradation via proteasome of GLIS3. Indeed, SUFU anchoring GLIS3 at the N-
terminus, hiding the residues recognized by the ubiquitin ligases, thus protecting and 
stabilizing GLIS3 activity [66, 69, 71]. Taken together these findings suggest that 
SUFU, belonging the SHH pathway, modulates GLIS3 functions by both cytoplasmatic 
stabilization and nuclear transcriptional regulation [61, 73].  
Furthermore, GLIS3 has been also described to interact with TAZ (WWTR1), a PDZ 
binding motif-containing transcriptional co-activator, in the primary cilium [74]. TAZ is 
part of the Hippo signalling pathway that regulates its nuclear localization and activity 
[69, 75]. The Hippo pathway plays a role in the regulation of many biological functions, 
including cell migration, differentiation, proliferation, and cell polarity. The WW-
domain of TAZ recognizes a P/LPXY motif in the C terminus of GLIS3 [74] [61].  
In vitro experiments demonstrate that the co-expression of these two transcription 
factors promotes the translocation of TAZ from the cytoplasm to the nucleus where it 
co-localizes with GLIS3. Into the nucleus, TAZ appears to function as a co-activator of 
GLIS3 enhancing its transcriptional activation. The localization at the primary cilium 
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and also the interaction with TAZ are reported to be the key elements of the GLIS3 
signalling pathway underlying the renal polycystic disease, described in patients with 
mutations in GLIS3 and WWTR1 [74, 76, 77].  
 
VII.  GLIS3  AND CONGENITAL HYPOTHYROIDISM 
 
Based on the current knowledge, GLIS3 represents a new candidate gene for congenital 
hypothyroidism (CH) but its role in thyroid development and function remains largely 
unexplored. 
Homozygous and compound heterozygous mutations in the GLIS3 gene have been 
associated with a rare syndrome, called NDH, characterized by neonatal diabetes (ND) 
and CH. NDH patients are characterized by intrauterine growth retardation and onset of 
non-immune diabetes mellitus (both Type-1 and -2). Other manifestations include renal 
parenchymal disease, primarily renal cystic dysplasia, and hepatic disease, with 
hepatitis in some patients and hepatic fibrosis and cirrhosis in others. Facial dimorphism 
and congenital glaucoma are also been reported in some affected cases [61, 65, 74, 78].   
Regarding the thyroid gland, high TSH and low T4 characterize all of NDH patients 
reported so far, but in presence of a wide spectrum of structural thyroid abnormalities 
including athyreosis, hypoplasia, perifollicular and interstitial fibrosis, and normal 
thyroid anatomy. Similar phenotypic variability has been also observed in patients with 
mutations in NKX2.1 and PAX8 genes, involved in the specification of thyroid 
primordium, and the subsequent expression of genes (TG, TPO, TSHR, and NIS) 
responsible for the differentiation and proliferation of thyroid follicles and the synthesis 
of thyroid hormones (TH) [79, 80].  
NDH patients are also characterized by variable sensitivity of TSH suppression after L-
thyroxine treatment, resulting in a difficult normalization of thyroid parameters [69]. 
Several patients with elevated TSH and TG levels appear to be resistant to increasing 
doses of thyroxine therapy despite normalisation of free T4, thus excluding alterations 
in the L-T4 absorption [68, 80].  
One possible explanation for the variable clinical manifestations described in patients 
could be attributed to the tissue-specific expression of variable-length transcripts of 
GLIS3, and the type of the mutation. The overall variants of the GLIS3 gene identified 
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in NDH patients include large or small frameshift deletions that mainly localised in the 
N-terminus, and point mutations within the ZF domain. It has been reported that large 
deletions or frame shift mutations, causing profound disruptions of GLIS3 structure, are 
associated with the most severe manifestations of NDH. Instead, milder phenotypes 
seem to be correlated to missense substitutions that preserve a residual function of one 
or more GLIS3 transcripts [69, 80].   
However, the lack of a distinctive clinical picture makes difficult the recognition and 
the treatment of these patients. Therefore, additional work is required to understand the 
genotype/phenotype correlations and, in particular, to determine whether GLIS3 acts 
upstream of genes involved in pathways regulating thyroid development, 
hormonogenesis, and the peripheral response to T4. 
In our laboratory, we have recently identified rare heterozygous GLIS3 missense 
variants in a large cohort (18/177) of patients with isolated CH [63]. Clinically, half of 
the affected cases presented variable thyroid dysgenesis (athyreosis, thyroid hypoplasia 
and ectopy), whereas the remaining part have in situ thyroid gland [63]. Interestingly, 
these GLIS3 variants are associated in all 18 cases with other rare variations in genes 
involved in thyroid pathology, supporting a frequent oligogenic origin of CH. 
Supporting our data, the NGS screening conducted in a cohort of 592 Chinese patients 
with CH reported a prevalence of the GLIS3 mutations of the 0.3% [81]. 
In addition, a number of genome wide association studies (GWAS) have associated 
several GLIS3 single nucleotide polymorphism (SNPs) with elevated circulating TSH 
levels and low T4 [61]. 
Taken together all of these data support a relevant role of GLIS3 in thyroid function and 
in the onset of CH, possibly contributing to the explanation of the missing hereditability 
of CH and the prevalent sporadic presentation of the disease [63].  
Although hypothyroidism is associated with GLIS3 variants, the absence of consistent 
pathological features in patients makes unclear the identification of a causative 
mechanism [69].  
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VIII.  ANIMAL MODELS OF NDH 
 
Up to now, the pathological mechanism underling the multisystem clinical presentation 
of NDH syndrome has been studied in mice, and most of the researches have been 
focusing on pancreas development and the onset of diabetes. 
The Glis3-null mice die within one week after birth due to the severity of neonatal 
diabetes [74]. The mutant mice Glis3zf/zf and Glis3-/- mutant mice develop neonatal 
diabetes, characterized by increasing blood sugar levels and decrease insulin secretion 
due to the early apoptosis of the β-cell mass [74, 82].  
Regarding the control of insulin secretion, it has been reported that Glis3 knockdown 
drastically reduces the expression of both Ins1 and Ins2 genes by the binding to specific 
GLIS-responsive elements located in their promoter regions. Both in vivo and in vitro 
data prove that Glis3 is able to physically interact with Pdx1, MafA and NeuroD1, 
forming a transcriptional complex that activate the expression of the Insulin genes [74, 
83]. Furthermore, the mRNA expression of the glucose transporter Glut2 and the ATP-
transporter SUR1 (Abcc8) are also reduced in the pancreas of Glis3-/- mice. SUR is a 
sensor of intracellular levels of ATP and ADP and enhance insulin secretion in response 
to anti-diabetic drugs. These data highlight the post-developmental role of Glis3 in 
controlling insulin transcription and secretion, thus explaining the pathological 
mechanism underlying the onset of T1D in NDH patients [84]. However, as T2D is 
concerned, the Glis3+/- mice develop overt diabetes and hypoinsulinemia when exposed 
to high-fat diet (HFD). Specifically, Glis3 deficiency is associated to downregulation of 
Ccnd2, a regulatory factor that is essential for postnatal β-cell growth and mass 
expansion in response to HFD and insulin resistance. An additional role of Glis3 in T2D 
is its association with apoptosis. Glis3 KD in INS-1 cells increases the expression of 
several inflammatory cytokines and modulating the alternative splicing of the pro-
apoptotic BimS leading to β-cells death [84].      
All of these studies indicate that GLIS3 has multiple critical regulatory functions during 
pancreas development and also in the adult pancreas: regulating the development of 
endocrine progenitors, the generations and maturation of pancreatic β-cells, regulation 
of insulin expression, as well as in maintaining normal duct morphology [69]. 
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As for NDH patients, the Glis3 mutant mice also develop polycystic kidney disease 
[77], pointing up the role of Glis3 in the maintenance of the normal renal function. 
Kang and co-workers demonstrate that Glis3 and its co-activator Wwtr1/TAZ are part 
of transcriptional regulatory networks that are critical in the function of the primary 
cilium [77].  
As far as thyroid gland is concerned, the Refetoff’s group has recently described that 
Glis3 is essential for TH biosynthesis and postnatal thyroid gland proliferation in 
mouse, acting down-stream of TSH/TSHR system [79]. In the mouse thyroid tissue, 
Glis3 is highly expressed into the follicular cells, co-localizing with Pax8 in the nuclei. 
Glis3 KO mice present decreased levels of both free and TG-bound T4 and T3 
accompanied with an elevation of TSH, suggesting its role in TH biosynthesis. RNA-
seq and CHIP-seq analyses of mice thyroid confirm that Glis3 directly regulates the 
expression of Nis, Pds, Tpo, Duoxa2 and Mct8, the key components of the TH 
biosynthesis machinery [79]. Furthermore, Glis3 deficiency results in structural changes 
of the thyroid gland that appears smaller size with a diminished number of follicular 
cells per follicle. Its role in follicles proliferation is further confirmed by the treatment 
of KO mice with low-iodide diet (LID). Both WT and Glis3 KO mice present a 
dramatic increase of TSH in presence to LID, but in contrast, the thyroid gland of Glis3 
KO mice fail to adequately respond to the activation of the HPT-axis with follicular 
hypertrophy [79]. Data obtained by gene-expression analyses also indicate that Glis3 
deficiency is associated with a strong down-regulation of several cell proliferation-
related gene, such as Ccnd2 and Cdca2 [79]. Interestingly, this scenario is similar to 
what was described in the pancreas during postnatal period, where the lack of Glis3 
leads to low insulin secretion and inability of the β-cells to growth and expanse their 
mass in presence of HFD. These results indicate that GLIS3 is primarily involved in the 
postnatal control of TH synthesis and follicle proliferation downstream the TSH/TSHR 
system [79].  The expression levels of Pax8, Nkx2.1, and Foxe1 are not significantly 
changed in thyroid glands from Glis3 KO mice. Although in the first week after birth, 
the size of the thyroid follicles is smaller in Glis3-deficient mice, the thyroid gland and 
the TH levels are well conserved, suggesting that the subsequent hypothyroidism in this 
particular KO model is related to a hormonogenesis disorder rather than to thyroid gland 
dysgenesis.  
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In mice, Glis3 appears to be important for the expression of Slc5a5 (Na/I Symporter) 
and Slc26a4 (Pendrin), channels responsible for iodine uptake and TH synthesis. The 
authors also report that the repression of proliferation of Glis3-deficient thyroid 
follicular cells is caused by the inhibition TSH-mediated mTOR pathway as well as the 
reduced expression of several genes involved in cell-division, which are directly 
regulated by Glis3. However, despite the relevant role of Glis3 described during 
pancreas organogenesis, no significant thyroid developmental defects were observed in 
Glis3
-/- mice. These data are partially in contrast to those observed in the NDH patients, 
in which thyroid dysgenesis is a common feature. However several factors, including 
the type and site of the mutation, can contribute the variable expression of the thyroid 
phenotype [79].  
Although the available Glis3 models greatly increase the comprehension of the 
molecular mechanisms underlying pancreas development and function, they not fully 
recapitulate the clinical manifestations of the NDH patients, in particular regarding the 
thyroid gland. Therefore, we address the possibility of zebrafish as a viable vertebrate 
model to study in more details the role of GLIS3 in thyroid dysfunction. 
 
 
IX.  ZEBRAFISH AS A MODEL TO STUDY THE ROLE OF GLIS3   
      DURING THYROID DEVELOPMENT 
 
Zebrafish (Danio rerio) has emerged as an important and useful model system to study 
different human diseases. Zebrafish possesses a unique combination of features that 
makes it particularly well suited for experimental and genetic analysis of vertebrate 
development. It has a short reproductive cycle with external fertilization and lays a large 
numbers of embryos per mating that can be analysed under microscope because of their 
optical transparency. Somitogenesis begins at about 9hpf and at 24hpf the zebrafish 
embryo has already formed all the major tissues and many organ precursors, such as a 
beating heart, circulating blood, nervous system, eyes and ears, all of which can be 
readily observed under a simple dissecting microscope. Larvae hatch by about 2.5dpf 
and they are swimming and feeding by 5–6dpf.  
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A variety of tools and methodologies have been developed to exploit the advantages of 
the zebrafish system. Zebrafish embryos and early larvae are optically clear, allowing 
for direct, non-invasive observation or experimental manipulation at all stages of their 
development, such as whole mount in situ hybridization analysis of gene expression 
patterns with extraordinarily high resolution. The microinjection of morpholinos (MOs), 
specific antisense oligonucleotides, is a useful method to investigate gene function in 
vivo by gene-specific inhibition of mRNA translation or by modifying pre-mRNA 
splicing events. It is possible to knockdown two or more different genes simultaneously 
by the injection of different MOs. Moreover, the genome editing techniques such as 
TALENs and CRISPR/CAS9 allow to generate stable mutant lines, permitting to 
overcome some limitations dictated by the morpholino microinjection [85]. 
Importantly, this model has been more and more frequently used in studies on thyroid 
pathophysiology because of its versatility, limited costs, and the relatively shortened 
time to obtain significant results when compared with other animal models as well as 
the broad conservation of the molecular mechanisms involved in thyroid development 
and function and TH action [2, 13, 17, 86]. 
 
 
X.  AIM OF THE PROJECT 
 
The aim of my PhD thesis is to deeply investigate the glis3 function during the early 
steps of thyroid gland development, taking advantages of the zebrafish model system. In 
particular, we focus the attention on the possible glis3 interaction with the SHH 
pathway during the commitment of the endocrine precursors towards the thyroid fate. 
The comprehension of the molecular mechanism of glis3 activity will provide new 
insights into the ethiopathogenesis of CH. 
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MATERIALS & METHODS 
	
	
	
	
	
	
	
	
	
	
	
I.  ZEBRAFISH MAINTENANCE  
 
• Ethical statement 
Current Italian national rules: no approval needs to be given for research on zebrafish 
embryos. Fish were maintained and raised according to EU regulations on laboratory 
animals (Directive 2010/63/EU). 
 
• Zebrafish line and maintenance  
Breeding fish were maintained at 28°C on a 14 hours light/10 hours dark cycle. They 
are bred in 3-5 litre tanks in three different systems.  
Embryos were collected by natural spawning and staged according to Kimmel et 
colleagues (1995) [87]. They were raised in an incubator at 28°C in fish water with 
0,1% Methylene Blue in petri dishes. The following Wild Type (WT) zebrafish line was 
used: AB strain, obtained from Wilson lab, University College London. 
Stock solution for fish water: 34 g of Instant Ocean Sea Salt dissolved in 1 l of deionised 
H2O.  
Fish water: 50 ml of stock solution in 10 l of deionised H2O. 
 
 
II.  REAL-TIME qRT-PCR 
 
Real-Time qRT-PCR (Real-Time Quantitative Reverse Transcription PCR) was used 
for the detection and quantification of cDNA targets. This technique used fluorescent 
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reporter molecules (SYBRTM Green) to monitor the production of amplification 
products during each cycle of the PCR. Before the Real-Time PCR, this technique 
required the extraction of RNA from tissues and then its retrotranscription in cDNA.  
 
A.    Total RNA extraction and cDNA synthesis 
 
Total RNA was extracted from embryos of different developmental stages and from 
several adult tissues using the TRIzolTM (Thermo Fisher Scientific). Tissues and organs 
were dissected under a stereomicroscope, frozen in TRIzolTM and stored at -80°C until 
further processing. Total RNA was extracted from pools of 20 embryos for each 
developmental stage and stored at -80°C. Frozen specimens were homogenized in 
TRIzolTM. The RNA was then purified according to standard protocols and resuspended 
the in 20–50µl of RNase- free water, 0.1mM EDTA, or 0.5% SDS solution. 
The reaction was carried out following the protocol of GoScriptTM Reverse 
Transcription System  (Promega). 
 
B.    Real-Time PCR  
	
	
Real-time analysis was performed by ABI PRISMTM 7900HT Fast Real-Time PCR 
System) using SYBRGreen MasterMix (Invitrogen).  
The PCR reaction comprised an initial denaturation step at 95 °C for 30 s, followed by 
40 cycles at 95 °C for 5 s, 60 °C for 15 s, and 72 °C for 45 s. A melting temperature-
determining dissociation step was performed at 95 °C for 30 s, 60 °C for 30 s, and 72 
°C for 60 s at the end of the amplification phase. The dissociation curve was used to 
check the specificity of PCR products. 
For each developmental stage and for each tissue 50ng of cDNA were used. Elongation 
factor 1-alpha 1 (eEF1a1) gene was used as endogenous control. Quantification of the 
targets was normalized using the comparative CT method (also known as the ΔΔCT 
method), after ensuring that the targets and endogenous control had similar or relatively 
equivalent PCR efficiencies. Each experiment was conducted as a triplicate and 
repeated three times.  
The following specific primers for the real-time PCR are used: 
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eef1a FW 5’ CTGGTGTCCTCAAGCCTGGTA 3’ 
eef1a REV 5’ ACTTGACCTCAGTGGTTACATTGG 3’ 
glis3_qRT_FW 5’ GACGCCAGCAGGTGTTTGCT 3’ 
glis3_qRT_REV 5’ CAGAGACTCTCTGGAGAGCA 3’ 
 
 
III.  SYNTHESIS OF PROBES FOR IN SITU  HYBRIDISATION  
 
To perform the whole mount in situ hybridisation assay we synthesised, in vitro, the 
glis3 antisense digoxigenin (DIG) riboprobe, that consequently binds to the endogenous 
glis3 mRNA during the hybridisation. In order to synthetize the probe we designed two 
primers to amplify a 1024bp long sequence for glis3 (ENSDART00000142833.2). Then 
we performed a RT-PCR reaction on total RNA extracted from WT 26-48hpf (hours 
post fertilisation) embryos. 
The primers used for probe amplification are the following: 
 
glis3_WISH_FW 5’ TGGGAAAGGCTGTAACCTGA 3’ 
glis3_WISH_REV 5’ GGACACCTCAAACTGAAGCG 3’ 
 
To evaluate the development and function of the thyroid we also used the following 
probes: nkx2.4, pax2a, tg, slc5a5 [56], tshba [88], shha [89], and wwtr1 [90].  
 
A.    Cloning and transformation reaction 
 
The RT-PCR product was cloned in the pCRTM II-TOPO® vector (Figure 11) following 
manufacturer’s instructions of TOPO TA Cloning® kit (Invitrogen), that provide for the 
cloning of PCR product in the plasmidic vector and then its bacterial transformation 
using One Shot® TOP10 (Invitrogen) competent cells.  
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Figure 11. Schematic representation of the pCR
TM 
II-TOPO
® 
vector. (from TOPO® TA Cloning® Kit 
user manual Invitrogen).  
	
	
B.     Isolation of plasmid DNA 
Recombinant colonies were screened and preparation of plasmid was performed using 
PureLinkTM HiPure Plasmid Filter Maxiprep system (Invitrogen) according to the 
manufacturer’s instructions.  
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C.     Probes labelling and synthesis 
 
The linearized plasmids were then used as templates for antisense digoxigenin-UTP 
labelling and for in vitro riboprobe synthesis following the DIG RNA Labelling Kit 
(SP6/T7; Roche) manufacturer’s instructions. 
 
 
IV.  WHOLE MOUNT IN SITU  HYBRIDISATION (WISH) 
	
Embryos at the appropriate stage were fixed in 4% paraformaldehyde (PFA)/ phosphate 
buffered saline (PBS) over night at 4°C; then they were dechorionated and they were 
dehydrated in 100% methanol and stored at -20°C until used for whole mount in situ 
hybridisation (WISH). WISH experiments were performed according to Thisse et al., 
[91].  
The synthetized DIG-probes were detected using anti-DIG-alkaline phosphatase (AP) 
and NBT/BCIP staining.  
After WISH experiments, the embryos were post-fixed in 4% PFA and analysed in 
glycerol 85% under a stereomicroscope.  
To evaluate the thyroid volume (tg) and the proper synthesis of tshba the respective 
DIG-probes were stained with Fast Blue that is able to produce fluorescent signals. 
These signals were detected by confocal microscopy. 
For confocal microscopy, fixed embryos were embedded with 0.8% low-melting 
agarose and placed on a Petri capsule. Stacks were recorded using a 40x immersion 
objective (Nikon C2+ confocal system; Nikon). The fluorescence signals were 
quantified using ImageJ software (http:// rsb.info.nih.gov/ij/). 
 
 
V.  LOSS-OF FUNCTION ANALYSIS  
 
The embryos were injected with a specific Morpholino (MO), a specific antisense 
oligonucleotide to transiently knock down the gene function. 
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The specific glis3 morpholino was designed by Gene Tools (LLC, Philomath, OR), in 
order to recognize the splice donor site of the exon2-intron2 boundary of the pre-
mRNA. 
 
- GLIS3MO_SPL:  5 ’- TTCTTGTTTTTACCTTTCATACCGC - 3’ 
 
As a negative control we injected standard control morpholino (std ctrl-MO) that targets 
human β-globin gene. This oligo has not been reported to have other targets or generate 
any phenotypes in any known test system except human β-thalessemic hematopoetic 
cells. 
 
- std ctrl-MO :    5’    CCTCTTACCTCAGTTACAATTTATA    3’ 
 
Morpholinos were dissolved in Danieau’s buffer (58mM NaCl; 0,7mM KCl; 0,4mM 
MgSO4.H2O; 0,6mM Ca(NO3)2; 5mM Hepes pH 7.2) at 2mM concentration and 
stored at –80°C. 
Embryos were microinjected at the 1–4 cells stage and Rodamine dextran (Molecular 
Probes) was usually co-injected as a tracer.  
Microinjection was performed through a micromanipulator (Micromanipulator 5171; 
Eppendorf), and a microinjector (Femtojet; Eppendorf.)   
Escalating doses of MO were tested for phenotypic effects and to establish the correct 
dose to perform the experiments.  
The embryos were treated with PTU 1X (1-Phenil-2-thiourea, SIGMA; stock PTU 10X 
0.015 g of PTU powder in 50 ml of fish water) to inhibit pigment formation [92]. 
For a better observation the injected embryos (called morphants) were anaesthetized 
using tricaine 1X (Ethyl 3-aminobenzoate methanesulfonate salt, SIGMA; stock tricaine 
25X 0.08 g in 20 ml of distilled H2O) in fish water and PTU 1X. 
The morphants were observed up to the stage of interest and they were fixed in PFA 
4%/PBS at 4ºC over night, dehydrated and stored in 100% MeOH at –20°C.  
RT-PCR and qRT-PCR on total RNA, extracted from 30–40 embryos at 2 days post-
fertilization (dpf), were used to found out the molecular mechanism of action and to 
check the efficiency of splicing MO.  
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The primers used for RT-PCR are the following: 
 
glis3_MO_FW 5’ AAACCGGGCCCTGATGAATA 3’ 
glis3_MO_REV 5’ AAGCAGGACTGAGACTCTGG 3’ 
 
The primers used for qRT-PCR are the following: 
WT_FW 5’ ATGAAAGGTTACAGAAGGGT 3’ 
WT_REV 5’ AGCAAACACCTGCTGGCGT 3’ 
Intr2_FW 5’ ATGAAAGGTAAAAACAAGAAT 3’ 
Intr2_REV 5’ ATTAGTTGACTTTACCTTCAAA 3’ 
 
To confirm the results obtained by the GLIS3MO_SPL, we used a second glis3 splicing 
morpholino (GLIS3_MO2) that has been already validated [93].   
 
- GLIS3_MO2: 5 ’- ACCTGCTGCAAGAGATCAGTTAAAA - 3’ 
 
To investigate the relationship between glis3 and Shh or Notch pathway the MOs used 
are the following, which have been already validated:  
 
- shha_MO: 5’ - CAGCACTCTCGTCAAAAGCCGCATT - 3’ [94] 
- jag1a_SPL_MO: 5’ - AAACAGCCTCTGAAACTCACCGGCC - 3’ [47] 
- jag1b_SPL_MO: 5’ - AATCCTGCTACTCACTTTCACTGGC - 3’ [47] 
 
 
VI.  RESCUE EXPERIMENTS 
 
Full-length zebrafish wild type glis3 cDNA was cloned into pcs2+ vector (Invitrogen; 
Figure 12) between BamhI and EcorI restriction sites, upstream the Sp6 promoter 
sequence and downstream the polyadenilation signal.  
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Figure	12. Schematic representation of the pcs2+ vector (Invitrogen).  
 
Primers used to obtain the full-length zebrafish glis3 coding sequence (CDS) are the 
following:  
 
glis3CDS_FW 5’ ATGGACATGAATGGGAAAG 3’ 
glis3CDS_REV 5’ TCAGCCTTCAGTGAACACACA 3’ 
 
After transformation in TOP10 cells, the wild type positive clone was selected and 
confirmed by complete automated sequencing. The mutated glis3 mRNA was generated 
introducing a point mutation GGA>TGA in the position 1223bp, causing the formation 
of a premature stop codon upstream the Zinc-Finger functional domain.  
The primers used for mutagenesis are the following:  
 
glis3MUT_FW 5’ TGCACTGCTGAGCCATCTACAGCC 3’ 
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glis3MUT_REV 5’ GGCTGTAGATGGCTCAGCAGTGCA 3’ 
 
Both constructs (wild-type and mutated) were linearized with Not1 and the efficiency of 
was checked on agarose gel electrophoresis. The mRNAs were in vitro transcribed 
using the mMessage mMachine Sp6 kit (Thermo Fisher Scientific), following the 
manufacturer’s instructions.  
The obtained mRNAs were purified using the phenol/chloroform extraction and 
quantified by Nanodrop. 
As control of glis3 mRNAs microinjection, we used the mRNA of GFP, which has no 
targets in zebrafish.  
 
 
VII.  IMMUNOFLUORESCENCE 
 
The qualitative analysis of TH production was performed by immunofluorescence 
according to standard procedures using the rabbit anti-T4 BSA serum (1:1000; ICN 
Biochemicals, Aurora, OH) and the AlexaFluor 555 anti-rabbit IgG as secondary 
antibody (Invitrogen) [11, 47].     
 
To test proliferation and apoptosis, after WISH with nkx2.4-DIG riboprobes and Fast 
Blue staining, embryos were stripped and rinsed in PBS. Anti-phospho-histone H3 
(PH3) and antiactive caspase-3 (AC-3) antibodies (1:250; Cell Signaling, Beverly, MA), 
followed by antirabbit IgG secondary antibody/AlexaFluor 488 (1:500; Invitrogen) were 
used [47].   
 
 
VIII.  IMMUNOCYTOCHEMISTRY 
	
COS7 cells were plated (2 × 105) on sterile coverslips placed in 35 mm Petri dishes and 
transfected with 1µg of plasmids (for co-transfection was used 0.5ug of pEGFP_sufu 
cDNA and 0.5ug of pcDNA4/His-Myc_A_glis3 cDNA). Twenty-four hours after 
transfection, cells were washed with PBS, fixed with PBS containing 3% 
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paraformaldehyde (Sigma-AldrichSt. Louis, MO, USA) for 10 min at room temperature 
and rinsed twice with PBS. Cells were permeabilized with 0.1% Triton X-100 (Sigma-
Aldrich, St. Louis, MO, USA), blocked for 30 min with PBS-goat serum 2% 
(Invitrogen, Auckland, NZ), incubated with α-c-Myc primary antibody 1:100 (Life 
Technologies, Carlsbad, CA, USA) in PBS-goat serum 2% (1:100) overnight at 4°C and 
incubated with the appropriate secondary antibodies (Alexa Fluor 555 goat anti-mouse 
IgG, Life Technologies, Carlsbad, CA, USA) 1:500 for1 h at room temperature. Finally 
cells were mounted with Slow-Fade Gold antifade reagent with Dapi (Life 
Technologies, Carlsbad, CA, USA). Images were acquired by using a laser scanning 
confocal system installed on a Nikon Eclipse Ti microscope with a 60x oil immersion 
objective. Alexa Fluor 555 was excited with a 555-nm argon laser and detected with a 
568-nm band pass filter. 
 
	
IX.  CYCLOPAMINE TREATMENT 
 
For the inhibition of the Shh pathways, embryos were rinsed in fish water with 10µM 
Cyclopamine (Sigma-Aldrich) from 50% epiboly stage up to fixation in PFA at 26 and 
48hpf. Controls consisted of corresponding incubations in 1%DMSO 
(dimethylsulfoxide) [95, 96].  
 
 
X.  DAPT TREATMENT 
 
For the inhibition of the Notch pathways, the γ-secretase inhibitor DAPT (N-[N(3,5-
difluorophenacetyl)-l-alanyl]-S-phennylglycine t-butyl ester) (Sigma-Aldrich)  was 
diluted in fish water at 100µM. The embryos were dechorionated and treated with 
DAPT from 50% epiboly stage up to 24hpf at 30°C. As controls, the embryos were 
treated with fish water containing 1% DMSO [47].  
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XI.  STATISTICAL ANALYSIS 
 
All data were shown as means ± standard error (SEM) or percentages. The t-student test 
was used to comparison of differences between groups. The p<0.05 was considered 
statistically significant (*p<0.05; ** p<0.01; ***p<0.001). All analyses were conducted 
with the software package GraphPad Prism 4.0 (GraphPad, San Diego, CA).  
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RESULTS 
 
 
 
 
 
 
 
 
I.  STRUCTURE AND CONSERVATION OF ZEBRAFISH GLIS3   
 
The glis3 gene is evolutionary conserved across species dating back to fishes. In 
zebrafish glis3 (NM_001080607) is localized on the chromosome 10 and encodes for a 
full-length protein of 804 aminoacids and 88.45kDa in size (UniProt F1QB13). 
Recently, a shorter isoforms (787aa) with unknown functions has been deposited 
(UniProt A0A0R4IU85).  
As reported in Figure 13, the full-length protein is composed of several domains. The 
Serine-Rich (SR) and Proline-Rich (PR) domains localized in the N-terminus seem to 
be important for the interaction with Hnf6, a critical regulator in early endoderm 
development (Kim, 2012). The five zinc-finger (ZF) motifs positioned in the middle of 
the protein are crucial for the recognition and binding of the GLIS3-binding sites 
(Glis3BS). Finally, the nuclear localization signal (NLS) partially overlapping with the 
5th ZF allows the translocation of the transcription factor into the nucleus.  
The alignment conducted with ClustalW2 software (www.clustal.org) revealed the 
rather low conservation between zebrafish and human (47.23%) or murine (46,52%), 
which is mainly restricted in the ZF domain (Figure 13B and C) [97].  
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Figure 13. (A) Schematic representation of the zebrafish glis3 protein (UniProt F1QB13). Yellow = 
Serine-Rich (SR) domain; Green = Proline-Rich (PR) domain; Light Blue = Zinc-Finger (ZF) domain; 
Red = Nuclear Localization Signal (NLS). (B) Alignment of the GLIS3 protein sequencing of the 
zebrafish (UniProt F1QB13), mouse (UniProt Q0GE24) and human (UniProt Q8NEA6). The colour code 
of the different domains is reported above. The residues that differ between species are highlighted in 
grey. (C) Aminoacid identity between zebrafish, murine and human GLIS3 proteins, performed using 
ClustalW2 software [97].  
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II. EXPRESSION OF GLIS3 DURING ZEBRAFISH DEVELOPMENT 
 
To explore the function of glis3 activity in vivo, we examined its expression in zebrafish 
embryos by qRT-PCR and WISH. Glis3 expression is dynamically regulated in a spatio-
temporally specific manner during embryonic development (Figure 14). 
As reported in the histogram 14A, glis3 mRNA has not maternal origin, since it was 
undetectable before the maternal to zygotic transition (MZT) stage, occurring at 2.5-
3hpf. The expression of the zygotic glis3 mRNA started from the late somitogenesis (20 
somite-stage, 19hpf) onwards. During the later phases of embryonic development and 
larval transition, the levels of glis3 increased exponentially by 3-5 fold at 1-3dpf, and 8-
fold at 5dpf [97].  
 
By WISH we also characterized the tissue-specific expression of glis3 during 
embryonic development. At 20hpf, glis3 is widely expressed in head and trunk regions 
(Figure 14C and C’), whereas at 24hpf, it appears restricted in brain, pronephric ducts 
and pharyngeal endoderm, the tissue that will give rise to the endocrine organs, such as 
thyroid and pancreas (Figure 14D). In particular, glis3 is expressed in a “salt and 
pepper” manner, in the portion of the endodermal pouches and the medial endoderm 
(Figure 14D’), and well localized with cells that constitute the pancreatic bud (Figure 
14D’’). At 36hpf, the mRNA was also detectable in the hypothalamus, medial 
endoderm, otic vesicle, and pronephric ducts (Figure 14E-E’).  At 2dpf, the signal is 
restricted to heart, hypothalamus and pronephric ducts (Figure 14F). Of note, glis3 is 
not detectable in the developed thyroid gland (2dpf).  
In adult zebrafish, the expression of glis3 is maintained at high levels in kidney, 
pituitary and pancreas. Lower levels of mRNA are also present in testis, ovary, brain 
and pectoral fins (Figure 14B). Given the lack of a compact thyroid gland in zebrafish, 
it was not possible to dissect the single follicles for the analysis of the glis3 expression 
[97]. 
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Figure 14. Ontogenetic pattern of glis3 expression in zebrafish. (A-B) qRT-PCR of glis3 relative 
mRNA expression during embryonic development and adult tissues. Total RNA is extracted from pools 
of 50 embryos/stage and from 3 adults, respectively. cDNA synthesis and qRT-PCR following standard 
procedures. Experiments are performed in triplicate and results are expressed by Mean ± SD. (C-F) 
Tissue specific expression of glis3, at different developmental stages, analysed by WISH using glis3 
antisense riboprobe followed by NBT/BCIP staining. Images are representative of three experiments (30 
embryos each). Embryos were acquired in lateral and dorsal view. Scale bars: 100µm and 250µm. B: 
brain; E: endoderm; PD: pronephric ducts; EP: endodermal pouches; ME: medial endoderm; PB: 
pancreatic bud; Hy: hypothalamus; OV: otic vesicles; H: heart. (G) Schematic representation of zebrafish 
pharyngeal region composed by the endodermal pouches (EP1-4), medial endoderm (ME), mesodermal 
core (MC), neural crest cells (NCC) and ectoderm (EC). Adapted from Rurale et al., 2018 [97]. 
 
 
 
III.  KNOCKDOWN EXPERIMENT WITH GLIS3  MORPHOLINO  
      ANTISENSE OLIGO  
 
To further characterize the role of glis3 in zebrafish embryonic development and during 
thyroid organogenesis and function in particular, we performed knockdown experiments 
by the microinjection of specific glis3 morpholino into zebrafish embryos (called 
morphants) and comparing them with controls.  
The control embryos were generated by the injection of a standard control morpholino 
(Std_CtrlMO) that has no target in zebrafish to discriminate possible off target effects or 
alterations due to the injection manipulation. 
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The spliced-blocking morpholino against glis3 was designed to recognize the splice 
donor site of the exon2-intron2-3 boundary of the pre-mRNA (glis3MO_SPL) 
(Figure15A). The glis3MO_SPL was validated injecting different doses (0.3, 0.5, 0.7 
and 1 pmol/embryo) in the zebrafish embryos at one-cell stage. The total RNA was 
extracted from pools of injected-embryos at 1 and 2dpf, and retrotranscribed into 
cDNA. The RT-PCR performed using a specific set of primers confirmed that the 
glis3MO_SPL alters in a dose-dependent manner the normal splicing, causing a strong 
reduction of the wild-type transcript and the production of a longer mRNA that retained 
part of the intron2-3 (340 bases) (Figure 15B). Additionally, by qRT-PCR we observed 
that the expression aberrant glis3 mRNA is correlated with the amount of the 
glis3MO_SPL injected (Figure 15C).   
The bioinformatic analysis of this aberrant transcript revealed the formation of a 
frameshift mutation and thus leading to the translation of a non-functional protein. 
  
 
Figure 15. Morpholino-mediated knockdown of the glis3 genes in zebrafish. (A) glis3 gene structure: 
the squared boxes correspond to the exons, the orange lines correspond to the introns. glis3SPL_MO is 
targeted to the splice donor site between exon 2 and intron 2-3 (E2i2-3). The position of primer sets used 
in RT-PCR and qRT-PCR to analyse the altered splicing are indicated in green and in blue, respectively. 
(B) RT-PCR analysis of glis3 expression in STD_Ctrl and glis3SPL_MO injected embryos at different 
doses. The glis3SPL_MO causes the retention of a part of intron2-3 producing   a PCR product of 340bp. 
(C) qRT-PCR of WT (mRNA WT) and aberrant (mRNA_intr2) glis3 transcripts expressed after injection 
of growing doses of glis3SPL_MO.   
 Results 
	
53
IV.  EVALUATION OF THE PHENOTYPE OF GLIS3  MORPHANTS  
 
During embryonic development, the glis3 morphants presented a series of 
morphological defects, which can be divided into three phenotypic classes: normal, 
moderate and severe (Figure 16). The normal ones are indistinguishable form the 
controls (Figure 16A, E and I) and developed without any visible alteration (Figure 
16B, F and L). The moderate class included morphants with curved tail, cardiac edema 
and impaired circulation (Figure 16C, G and M). The third class displayed severely 
affected phenotypes: shortened body, small head, cardiac edema, notochord 
abnormalities and twisted or truncated tail (Figure16D, H and N).  The frequencies of 
the morphants belonging these 3 phenotypic classes were strongly dependent on the 
dose of glis3MO_SPL injected (Figure 16O). Since the highest dose (1pmol/e) was 
associated with the most severe phenotype and with the higher mortality, we decided to 
use the 0.3 and 0.5pmol/e for the subsequent analysis.  
 
Figure 16. Phenotypic classes of embryos injected with glis3MO_SPL. (A_N) Three phenotypic 
classes normal, moderate and severe analysed at three different developmental stages (1, 2, and 3 dpf). 
The normal embryos (B, F and L) are indistinguishable form the controls (A, E and I). The moderate 
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class (C, G and M) presents embryos with curved tail, cardiac edema and impaired circulation. The 
severe embryos (D, H and N) are strongly affected by necrosis, cardiac edema, reduced circulation and 
stasis. (Graphic O): frequencies of the morphants belonging these phenotypic classes according to the 
injected doses. Scale bar: 250µm.  
	
 
V.   GLIS3  KNOCKDOWN AND THYROID DEVELOPMENT 
 
Following the set up of glis3 gene knockdown and embryonic phenotype analysis, we 
performed whole mount in situ hybridization to test whether glis3 plays a role in 
zebrafish thyroid organogenesis. To this purpose, we analysed the expression of the 
early transcription factors nkx2.4 and pax2a, and the differentiated markers tg and 
slc5a5 at different time points.  
All of the results were confirmed by using a second glis3 splicing morpholino that had 
been previously validated [93] (data not shown).  
 
A.      Induction of thyroid primordium  
 
The thyroid primordium originates form the pharyngeal endoderm by 1dpf and starts to 
differentiate in thyroid precursors thanks to the combined expression of nkx2.4, pax2a, 
hhex and pax8 [56]. 
At 1dpf, the glis3 morphants exhibited a deficient formation of thyroid primordium with 
a reduction or absence of nkx2.4 and pax2a expression (Figure 17A-C and E-G).  
After WISH, we acquired the embryos in dorsal view and we quantified the volume of 
nkx2.4 and pax2a in the thyroid primordium (Figure 17A’-D’ and E’-H’).  
Regarding nkx2.4, the 34.4% of embryos injected with 0.3pmol/e of glis3MO_SPL was 
comparable to controls; the 42.8% presented a marked reduction of the nkx2.4 signal 
that was instead undetectable in the remaining 22.8%. Consistently with the lower 
levels of the wild-type transcripts, the 74.3% of the embryos injected with 0.5pmol/e, 
the nkx2.4 signal was absent, while it appeared reduced in the remaining 25.7% of the 
morphants (Figure 17D). 
The evaluation of pax2a gave similar results (Figure 17E-G). At 0.3pmol/e we 
observed: normal expression in the 48.5% of morphants, reduced or absent expression 
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in 17.6% or 33.9%, respectively. At 0.5pmol/e, the expression of pax2a was reduced or 
absent in the 31.2% and 68.8% of morphants, respectively (Figure 17F).  
Regarding the volume of thyroid primordium quantified in embryos classified as 
reduced or absent expression of nkx2.4 and pax2a we observed a  >50% and >95% 
reduction than normal embryos, respectively (Graphs D’ and H’).  
 
 
 
Figure 17. Expression of nkx2.4 and pax2a in the developing thyroid primordium (TP).  
(A-C and A’-C’) WISH of nkx2.4 expression in embryos injected with Std-CtrlMO and glis3MO_SPL at 
0.3 and 0.5pmol/e. Images are representative of injected embryos that expressed normal, reduced or 
absent nkx2.4 signal acquired in lateral and dorsal view. (E-G and E’-G’) pax2a expression in the 
injected embryos at 1dpf. The embryos were subdivided belonging the three phenotypic classes described 
above. Each experiment was performed in triplicate, using 40 embryos per MO injected. Scale bar: 
250µm. TP: thyroid primordium. (Graphs D, H) Bars indicated the percentages of the injected embryos 
belonging the different phenotypic classes. (Graphs D’, H’) Quantification of nkx2.4 and pax2a at 1dpf 
in the control and morphant embryos belonging the thyroid phenotypic classes (Normal; Reduced and 
Absent).  Data were obtained from 10 embryos for each class. Statistical significance was calculated 
using Student’s t-test (***P<0.001). 
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B.      Differentiation and proliferation of thyroid follicles 
 
At 2dpf the precursors of thyroid primordium differentiate into thyroid follicles, which 
express the functional markers tg and slc5a5, and proliferate along the ventral aorta by 
3dpf [98].  
In agreement with what previously described, at 2dpf the embryos injected with 
0.3pmol/e and 0.5pmol/e exhibited a dramatic reduction of tg in the 51.7% and 74.4%, 
respectively (Figure 18A-C). Similarly, comparing with the normal slc5a5 expression 
(Figure 18D), we observed a marked reduction in the 42.6% of morphants injected with 
0.3pmol/e and the 32.3% of 0.5pmol/e (Figure 18E and G). Furthermore, in the half of 
latter ones, the slc5a5 signal was undetectable (Figure 18F and G).   
At 3 dpf, the thyroid gland elongates in the midline forming the classical V-shape 
(Figure 18H). In morphants, the staining of tg continued to be reduced in the 32% and 
50% of embryos injected with 0.3pmol/e and 0.5pmol/e, respectively (Figure 18I and 
K). Notably, a considerable number of morphants exhibited a normal expression of tg 
but the thyroid follicles were disorganized and ventrally displaced along the ventral 
aorta (Figure 18J). 
After WISH, we flat mounted the embryos and counted the number of cells expressing 
tg and slc5a5. The number of positive cells in normal, reduced or disorganized thyroid 
tissues was calculated by dividing the area of positive staining by the average area of a 
single cell (Figure 18Land M). The difference between embryos with normal and 
reduced tg expression was significantly different at both 2 dpf (N: 48.5 ± 2,9; R: 15.2 ± 
1.8; P<0.001) and 3 dpf (N: 79.45 ± 4.3; R: 10.8 ± 2; P<0.001). No significant 
differences between normal and disorganized signal have been observed in the embryos 
stained with tg (N: 79.45 ± 4.3; D: 74.7± 3.9; P=ns).  Similarly, at 2 dpf, the number of 
slc5a5 expressing cells in normal embryos (N: 51.2 ± 2,3) was significantly higher 
compared to reduced (R: 18,7 ± 2,5; P<0.001) and absent (A: 0.45 ± 0.05; P<0.001) 
signals.  
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Figure 18. Expression of tg and slc5a5 in the developing thyroid gland. (A-B) WISH of tg expression 
in embryos injected with Std-ctrlMO and glis3MO_SPL at 0.3 and 0.5pmol/e. Images are representative 
of injected embryos that expressed normal or reduced tg signal. (D-F) slc5a5 expression in the injected 
embryos at 2dpf as described above. The embryos were subdivided belonging these three phenotypic 
classes: normal, reduced or absent. (D-F) analysis of thyroid elongation using WISH of tg, in the injected 
embryos at 3dpf. Morphants presented, at various degrees, a normal formation of the V-shape thyroid, a 
reduction or a disorganization of follicles. (Graphs C, G and K) Bars indicated the percentages of the 
injected embryos belonging the different phenotypic classes. Each experiment was performed in 
triplicate, using 40 embryos per MO injected. Embryos were acquired in ventral view, anterior to the left. 
Scale bar: 250µm. (Graphs L and M) Quantification of tg and slc5a5 expressing cells at 2 and 3 dpf in 
the control and morphant embryos belonging the thyroid phenotypic classes (Normal = N; Reduced = R; 
Disorganized = D and Absent = A). Data were obtained from 10 embryos for each class. Statistical 
significance was calculated using Student’s t-test (***P<0.001).   
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C.     Proliferation and apoptosis of thyroid primordium of glis3 morphants 
 
The mechanisms underlying the altered thyroid phenotype after glis3 knockdown were 
investigated by WISH of thyroid primordium using nkx2.4 followed by activated 
caspase-3 (AC-3) and phospho-histone H3 (PH3) immunostaining as markers of 
apoptosis or proliferation, respectively (Figure 19). At 24hpf, no significant differences 
in AC-3 (Figure 19C-D) or PH3 (Figure 19E-F) immunostaining were seen by confocal 
microscopy in the area of nkx2.4 expression in all morphants analysed. These findings 
confirmed that the reduced expression of the early thyroid markers was not associated to 
a decreased proliferation nor to an increased apoptosis of the endocrine precursors 
committed to thyroid fate.  
 
At this point we wondered if the reduced expression of the thyroid primordium in the 
glis3 morphants is the result of a global impairment of the pharyngeal endoderm. To 
explore this possibility we analysed the expression of foxa2, an early endoderm-specific 
transcription factor (Figure 20). When the thyroid start to develop (22hpf) the endoderm 
appeared unaffected in glis3 morphants (Figure 20B), compared to controls (Figure 
20A).  
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Figure 19. Analysis of apoptosis and proliferation in glis3-morphants. (A-F) WISH of nkx2.4, at 
1dpf, using FastBlue staining for the acquisition of the fluorescence signal, followed by activated 
caspase-3 (AC-3) (C-D) and phospho-histone H3 (PH3) (E-F) immunostaining. Std-ctrl embryos reveal 
the correct development of the thyroid primordium. In glis3-morphants the thyroid primordium is absent. 
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No differences in AC-3 or in PH3 immunostaining were observed in morphants, compared to controls. 
(C’-D’ and E’-F’) AC-3 and PH3 staining of the trunk-tail regions were used as control of experimental 
conditions. Each experiment was performed in triplicate, using 40 embryos per MO injected. (A-B) 
Embryos were acquired in lateral view; scale bar: 250µm. (C-F) Embryos are all flat mounted, in ventral 
view, with anterior to the left. Scale bar: 100µm. HY: hypothalamus, TP: thyroid primordium.  
	
 
	
 
Figure 20. Analysis pharyngeal endoderm in glis3 morphants. WISH showing foxa2 expression in 
Std_Ctrls (A) and glis3 morphants (B) at 22hpf. Each experiment was performed in triplicate, using 40 
embryos per MO injected. The embryos were acquired in dorsal view, anterior to the left. Scale bar: 
100µm. 	
	
	
	
D.     T4 production and regulation of the HPT-axis in glis3 morphants  
 
We performed T4 whole mount antibody staining to assess the status of thyroid function 
in glis3-injected larvae and controls at 5dpf. In control larvae, a growing number of T4-
producting follicles was detectable in the pharyngeal area, spread in the pharyngeal jaw 
(Figure 21A). ). By counting the single T4-positive follicles, we observed that the glis3 
morphants (0.5pmol/e) exhibited the reduced number of follicles (n: 3±1) compared to 
the control fish (n: 5±1) (Figure 21B and C).  
Given the primary regulatory role of TSH on thyroid function, we also investigated the 
expression of the pituitary tshba (homologous of the human TSHβ), by WISH using the 
FastBlue dye followed by confocal acquisition (Figure 21D-E).  At 5dpf, the 85% of the 
glis3 morphants (0.5pmol/e) presented a significant increased in the number of the tshba 
positive cells (n: 13±2) when compared with controls (n: 4±1) (Figure 21D-F).  
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Figure 21. Analysis of T4 and tshba levels in glis3-morphants. (A-B) T4 whole mount antibody 
staining, at 5dpf, in control and in glis3MO_SPL larvae at 0.5pmol/e. Distinct follicles were visible in a 
row along the anterior-posterior axis, at the pharyngeal midline. (C) Count of the number of T4-
producing follicles in Std_CtrlMO and in glis3MO_SPL injected larvae. (D-E) WISH of tshba using 
FastBlue staining for the acquisition of the fluorescence signal, at 5 dpf, in control and in glis3MO_SPL 
larvae at 0.5pmol/e. (F) Count of the number of tshba-producing follicles in Std_CtrlMO and in 
glis3MO_SPL injected larvae. Embryos were all flat mounted, in ventral view, with anterior to the left. 
Each experiment was performed in triplicate, using 40 embryos per MO injected. Scale bar: 100µm. 
Statistical significance was calculated using Student’s t-test (**P<0.01; ***P<0.001).    
  
	
Taken together, our results indicated that glis3 is involved zebrafish thyroid 
development. The knockdown of glis3 was associated with an early impairment of 
thyroid primordium induction thus leading to the differentiation of a reduced number of 
thyroid follicles.  
This defect was not associated to changes in proliferation/apoptosis of thyroid 
precursors, suggesting a role of glis3 for the quantitative regulation of endodermal 
precursor specification, thus restricting the number of cells committed to a thyroid fate. 
In later stages the low T4 production and the high tshba expression observed in glis3 
larvae well recapitulate the clinical findings described in patients with congenital 
hypothyroidism.  
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VI.  RESCUE OF THYROID DEFECTS OF GLIS3  MORPHANTS  
 
To have a confirmation of the specific thyroid phenotype resulting from glis3 
morpholino activity, we performed mRNA rescue experiments co-injecting the 
glis3MO_SPL with the wild type and mutated forms of the zebrafish glis3 transcript. 
The mutated glis3 mRNA was generated introducing a point mutation GGA>TGA in 
the position 1223bp, causing the formation of a premature stop codon upstream the ZF 
domain.  
Considering that glis3MO_SPL-injected embryos showed curved trunk, pericardial 
edema, and impaired circulation, independently of the class they belong to, we decided 
to check the recovery of these specific features, in association with a moderate mortality 
and reduced number of morphants with severe phenotype. Since high doses of mRNA 
injection resulted in increased mortality, the zebrafish embryos co-injected with 0.5 
pmol/e of glis3MO_SPL and 100pg/e of the WT or MUT glis3 mRNAs gave the best 
results, with a recovery of a normal phenotype in 50-60% of embryos with the affected 
phenotype of the glis3 morphants.  
In this experiment, the control embryos were generated by the injection of 100pg/e 
mRNA of GFP that has no target in zebrafish and does not cause any modification in 
the injected embryos. 
 
At this point, we focused our attention on the thyroid phenotype, analysing the 
expression of nkx2.4 and tg at 1 and 2dpf, respectively (Figure 22). No changes in the 
expression of both markers have been observed in the uninjected (Figure 22A and F) or 
in embryos injected with the GFP mRNA (Figure 22B and G). The co-injection with the 
glis3MO_SPL and the WT mRNA was able to normalize the expression of nkx2.4 and 
tg in the vast majority of the embryos (Figure 22D and I), in comparison with the 
glis3MO_SPL injected alone (Figure 22C and H). Interestingly, the co-injection of the 
glis3MO_SPL and the MUT mRNA (Figure 22K) failed to rescue the thyroid defects of 
glis3 morphants and even worsened the phenotype. Finally, no significant differences 
were observed after the injection of 100pg/e of both WT and MUT mRNA alone 
(Figure 22E, J and L). 
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Figure 22. Molecular analysis of the rescue of thyroid defects of glis3 morphants. (A-E) WISH of 
nkx2.4 expression, at 1 dpf, in the uninjected embryos, embryos injected with mRNA GFP 100pg/e, 
glis3MO_SPL at 0.5pmol/e, with both glis3MO_SPL at 0.5pmol/e and glis3 mRNA WT100pg/e and only 
glis3 mRNA WT100pg/e. (F, L) WISH of tg expression, at 2 dpf, in the uninjected embryos, embryos 
injected with mRNA GFP 100pg/e, glis3MO_SPL at 0.5pmol/e, with both glis3MO_SPL at 0.5pmol/e 
and glis3 mRNA WT100pg/e (I) with only glis3 mRNA WT100pg/e (J), with both glis3MO_SPL at 
0.5pmol/e and glis3 mRNA MUT100pg/e (K) and with only glis3 mRNA MUT100pg/e (L). Each 
experiment was performed in triplicate, using 40 embryos per each injection.  Embryos were acquired in 
lateral (A-E) and ventral (F-L) views, anterior to the left. Scale bar: 250µm.  
 
 
VII.  EFFECTS OF GLIS3  OVEREXPRESSION ON THYROID    
       DEVELOPMENT 
 
To further define whether glis3 gene dosage contribute to the onset of thyroid defects, 
we performed an over-expression experiment, microinjecting growing doses of WT 
glis3 mRNA. When compared with controls at 1dpf (Figure 23A), the injection of 200 
or 250pg/e was associated with an increase of the nkx2.4 signal at the level of the 
thyroid primordium in 56.5% or 68% (Figure 23B,C) of the embryos, respectively. 
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Similarly, we observed an upregulation of tg expression at 2dpf in the 68% (200pg/e) 
and 75% (250pg/e) of embryos (Figure 23D-F). 
 
 
Figure 23. Expression of nkx2.4 and tg in the glis3-overexpressed embryos. (A-C) WISH of nkx2.4 
expression in embryos injected with GFP RNA 250pg/e (Ctrl) and glis3 mRNA WT at 200pg and 
250pg/e. (D-F) WISH of tg expression in embryos injected with GFP RNA 250pg/e (Ctrl) and glis3 
mRNA WT at 200pg and 250pg/e. Embryos were acquired in lateral view (A-C) and in ventral view (D-
F). Each experiment was performed in triplicate, using 40 embryos per each doses injected. Scale bar: 
250µm. 
 
 
To quantify the impairment of thyroid specification after glis3 knockdown as well as the   
induction of thyroid growth following glis3 overexpression, we measured the tg and T4 
levels in embryos injected with glis3MO_SPL (0.5pmol/e) and the WT mRNA 
(200pg/e). At 2dpf, the injected embryos were analysed by WISH (FastBlue) of tg 
followed by confocal acquisition and quantification. ImageJ software was used to 
quantify both the number and the intensity of fluorescent pixels of the same area and 
number of stacks for each sample, thus defining the volume of tg-positive cells. In 
parallel, the number of T4-producing follicles in embryos at 5dpf was determined by 
IHC and fluorescence acquisition.  
Confirming the previous results, the thyroid gland was smaller in 87% of glis3 
morphants compared to controls (Figure 24A, B and D) and the number of T4-
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producing follicles was reduced by 50% (Figure 24E, F and H). On the contrary, the 
overexpression of glis3 led to an enlargement of the thyroid gland (+130% than 
controls) at 2dpf (Figure 24C and D), as well as in a significant increase of the T4 
production (Figure 24G and H).  
Taken together these data support the idea that glis3 is a key regulator of thyroid 
development, and that the proper amount of glis3 is critical for the adequate 
specification of thyroid precursors. 
 
 
 
Figure 24. Analysis of tg and T4 levels in glis3 overexpressing embryos. (A-C) WISH of tg using 
FastBlue staining for the acquisition of the fluorescence signal. Std_Ctrl embryos revealed the normal 
distribution of tg-expressing cells at 2dpf. (D) Quantification of the thyroid volume (µm3) in Std_Ctrl, 
glis3MO_SPL and glis3_mRNA 200pg/e injected embryos. The bars indicate the average of the total 
thyroid volume of 10 embryos per group. (E-G) T4 whole-mount antibody staining in larvae at 5dpf. 
Distinct follicles were visible in a row along the anterior-posterior axis, at the pharyngeal midline. (H) 
Count of the number of T4-producing follicles in Std_Ctrl, glis3MO_SPL and glis3_mRNA injected 
larvae. Embryos were all flat mounted, in ventral view, with anterior to the left. Scale bar: 100µm. 
Asterisks indicate statistically significant differences (Mann-Whitney test; ***, P<001).  
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VIII.  GLIS3  ACTS AS AN EFFECTOR OF THE SONIC-
HEDGEHOG PATHWAY 
 
Several findings support the idea that glis3 is one of the transcription factors belonging 
to the Sonic-Hedgehog (SHH) signalling: i) the members of GLI-family are reported to 
be the main effectors of the SHH pathway [50]; ii) the stability of the GLIS3 is 
regulated by the binding with the Suppressor of Fused (SUFU), a negative regulator of 
SHH [71]; iii) SHH is known to be an important regulator of endoderm specification 
and thyroid development [52]. 
To study the relationship between glis3 and Shh, we first analysed the expression of 
shha in glis3 morphants by WISH. When compared with controls at 2dpf (Figure 25A-
A’), the 100% of glis3 morphants injected 0.3pmol/e and 0.5pmol/e, presented a 
significant reduction of shha expression in the pharyngeal endoderm (Figure 25B-B’). 
Interestingly, the shha signal appeared upregulated in the hypothalamus and nervous 
system of morphants (Figure 25B-B’).  
 
 
 
Figure 25. Expression of shha in the glis3 morphants. (A-B) WISH of shha expression in embryos 
injected with Std-ctrl (A-A’) and glis3MO_SPL at 0.5pmol/e (B-B’). Each experiment was performed in 
triplicate, using 40 embryos per MO injected. Embryos were acquired in lateral (A, B) and dorsal (A’-B’) 
views, anterior to the left. Scale bar: 250µm. En: endoderm; Hy: hypothalamus.  
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To further confirm this association, we blocked the Shh signalling by the microinjection 
of a morpholino against shha [94] and by the treatment with the Shh antagonist 
cyclopamine and we analysed the expression of glis3. Cyclopamine is a 
pharmacological inhibitor of the Shh receptor smoothened (SMO), that through its 
binding to the receptor SMO is able to block the downstream Shh signal [95, 96]. 
When compared with controls at 1 and 2dpf (Figure 26Aand C), the injection of 
shha_MO (1.25pmol/e) abolished the expression of the glis3 in brain and in the 
pharyngeal endoderm (Figure 26B and D). Similar results were obtained by the 
treatment with 10µM of cyclopamine (Figure 26E-H).  
 
 
 
Figure 26. Analysis of glis3 expression in shha-deficient embryos.  (A-H) WISH of glis3 expression at 
1 and 2dpf. (B-D) The glis3 expression is absent, at the endoderm level, in the embryos injected with 
shha_MO at 1.25 pmol/e. (F-H) The treatment with Cyclopamine 10µM abolish the glis3 expression, 
compared with DMSO controls (E-G). Each experiment was performed in triplicate, using 40 embryos 
per each experiment. Embryos were acquired in lateral view, anteror to the left. Scale bar: 250µm.   
 
 
A.      Shh and zebrafish thyroid development 
 
To test whether SHH signalling plays a role in thyroid development, we blocked the 
SHH pathway by Cyclopamine and analysed the expression of thyroid markers by 
WISH (Figure 27).  
At 1dpf, both nkx2.4 and pax2a signals were absent at the level of thyroid primordium 
in the 100% of the cyclopamine-treated embryos (Figure 27A-D). At 2 and 3dpf, the tg 
expression was reduced in 68% or absent in 32% of treated-embryos (Figure 27E-K).   
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Figure 27. Analysis of thyroid gland development in Cyclopamine treated embryos. (A-D) WISH of 
nkx2.4 and pax2a expression at 1dpf in control embryos (DMSO1%) and treated with Cyclopamine 
10µM. (E-J) WISH of tg expression at 2 and 3dpf in control embryos (DMSO1%) and treated with 
Cyclopamine 10µM. The embryos were subdivided as normal, reduced or absent tg signal. The frequency 
of the embryos belonging each phenotypic class is reported in the histogram K. Each experiment was 
performed in triplicate, using 40 embryos per treatment. Embryos were acquired in lateral (A-D) and 
ventral (E-J) views, anterior to the left. Scale bar: 250µm. TP: thyroid primordium.  
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B.     Shh and glis3 overexpression  
 
To further investigate the role of Shh-glis3 pathway in thyroid development, we first 
analysed the expression of shha in glis3-overexpressing embryos. At 2dpf, no 
alterations of the shha signal at the level of the pharyngeal endoderm and nervous 
system have been observed in these conditions (Figure 28A-D). However, the 
overexpression of glis3 resulted in an excess of tg-expressing cells (see Section 7). 
When compared with controls (Figure 28E), the treatment with cyclopamine was able 
the abolish the expression of tg even in the glis3-overexpressing embryos (Figure 28H), 
similarly to what happened in fish with normal glis3 expression (Figure 28F).   
These results suggest that glis3 acts downstream the SHH pathway, likely controlling 
the specification of the endoderm precursors committed to the thyroid fate, and that Shh 
is necessary for glis3 activity.  
 Results 
	
70
	
Figure 28. Analysis of shha in glis3 overexpressing embryos. (A-D) WISH of shha expression in 
embryos injected with GFP mRNA 200pg (Ctrl) and glis3 mRNA WT 200pg/e at 2dpf. No differences 
are detectable between Ctrl and glis3 overexpressing embryos. (E-H) WISH of tg expression, at 2dpf, in 
embryos injected with 200pg of GFP and glis3 WT mRNAs, followed with treatment with DMSO1% and 
Cyclopamine 10µM. The cyclopamine treatment abolishes the expression of tg in the glis3-
overexpressing embryos (H). Each experiment was performed in triplicate, using 40 embryos for each 
experiment. Embryos were acquired in lateral (A, C), dorsal (B, D) and ventral (E-H) views, anterior to 
the left. Scale bar: 250µm. 
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C.     In vitro analysis of glis3 and sufu cellular localization 
	
Given the findings that demonstrated the importance of the interaction between Sufu 
and Glis3 for its cellular localization and transcriptional activity [71], we also wondered 
if this mechanism is conserved also in zebrafish.  
COS7 cells were co-transfected with plasmids that contained the entire coding 
sequences of zebrafish sufu and glis3.  As reported in Figure 29, glis3 co-localized with 
sufu into the nucleus of transfected cells, whereas a fraction of sufu is detectable into 
the cytoplasm.   
 
	
	
 
Figure 29.  Immunolocalization of zebrafish sufu and glis3 in COS7 cells. pEGFP_sufu is visible in 
green whereas the pcDNA4/His-Myc_A_glis3 was incubated with secondary antibody Alexa Fluor 555 
and is visible in red. Dapi  (in blue) marks the nucleus of cells. The experiment was performed in 
triplicate.	
 
 
IX.  ANALYSIS OF POSSIBLE GLIS3-NOTCH  
      PATHWAY INTERACTION 
 
Several findings, previously obtained in our Lab, demonstrated that Notch signaling is 
important for the correct thyroid development and function [47]. Differently, TAZ 
(transcriptional co-activator with PDZ-binding motif), also referred as Wwtr1, acts as a 
potent regulator of Pax8 and Nkx2, suggesting that TAZ within the hippo pathway may 
play a role in the control of the thyroid gland development [99]. It was also shown that 
both Glis3 and Wwtr1 contribute to renal function [77]. Since wwtr1 is known to 
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interact with the Notch signaling for the determination of cell fate in the zebrafish 
pronephric duct [100], we hypothesized a possible interaction between glis3 and wwtr1 
during thyroid development. For these reasons we decided to investigate the possible 
glis3 interactions with both Notch pathways and wwtr1 in the zebrafish thyroid 
development.  
Firstly, we decided to analyse by WISH the glis3 expression after down-regulation of 
the Notch signaling through the treatment with DAPT, an inhibitor of the Notch 
signaling, and through the injection of both MO against jag1a and jag1b [47]. Jag1a and 
jag1b are the ligands of the Notch receptors; it has been demonstrated that, in zebrafish, 
the knockdown of both genes results in thyroid hypoplasia and TSH elevated levels 
[47].  
At 24hpf, the glis3 expression in the embryos treated with DAPT 100µM [47]  (Figure 
30A-B) was unaffected.  
The same result was obtained by in the jag1a + jag1b morphants, in which glis3 signal 
remained unchanged, compared to control embryos (Figure 30C-D). 
 
 
Figure 30. Analysis of the possible glis3-Notch pathway interaction. (A-B) WISH of glis3 expression 
in embryos treated with 1%DMSO and 100µM DAPT, at 24hpf. No alterations in glis3 signal are 
observed compared to controls. (C-D) WISH of glis3 expression in embryos injected with Std_CtrlMO 
and jag1aMO+jag1bMO at 24hpf. The glis3 expression in the jag1-morphants is maintained. Each 
experiment was performed in triplicate, using 40 embryos per each experiment. Embryos were acquired 
in lateral view, anterior to the left. Scale bar: 250µm.  
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Then, we analysed the wwtr1 expression in the glis3MO_SPL injected embryos at 0.5 
pmol/e and no differences were observed in the wwtr1 signal in the glis3-morphants at 
both 26 and 48hpf (Figure 31).  
 
 
Figure 31. Analysis of wwtr1 in glis3-morphants. (A-D) WISH of wwtr1 expression in embryos 
injected with Std_CtrlMO and glis3MO_SPL at 0.5pmol/e at 26 (A-B) and 48hpf (C-D). The wwtr1 
expression in the glis3-morphants was unaffected. Each experiment was performed in triplicate, using 40 
embryos per each experiment. Embryos were acquired in lateral view, anterior to the left. Scale bar: 
250µm.  
	
Taken together, these results indicated that glis3-Shh and jagged-Notch and wwtr1-
Hippo pathways act in an independent manner during the early phases of the zebrafish 
thyroid formation. 
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Although a clear phenotype/genotype correlation has not been observed in CH, several 
factors, including type and site of mutation, should be taken in consideration [79]. 
Hence, there is an urgent need to improve our understanding in the pathophysiology 
underlying GLIS3 action, specially to determine whether GLIS3 acts upstream of genes 
involved in pathways regulating thyroid development, hormonogenesis, and the 
peripheral response to T4. 
To better characterize the role of GLIS3 in the CH pathogenesis and to overcome the 
limits of the KO mouse model, we decided to take advantage of the zebrafish model to 
deeply investigate the glis3 role in particularly during the thyroid gland development 
and function. Zebrafish is widely used in thyroid research thanks to the easy genetic 
manipulation, the rapid development and the high conservation of the pathways 
involved in thyroid morphogenesis [13, 17, 20].  
Although the knockdown of glis3 has been previously associated with pancreatic and 
renal dysfunction in zebrafish [61, 90, 93], few data are available in literature regarding 
its expression and activity. Therefore, we first analysed in silico the protein structure of 
the zebrafish glis3 in comparison with the mammalian orthologues. Despite the low 
conservation between the zebrafish and human or mouse GLIS3 proteins, we observe 
high identity in the zinc-finger functional domain, suggesting that the molecular 
mechanism of the transcription factor can be evolutionary conserved.  
The analyses of the temporal and tissue-specific expression indicate that glis3 is 
detectable at higher levels from 1dpf onwards in brain, pronephric ducts, and in pouches 
and medial region of pharyngeal endoderm, emphasizing its possible involvement 
during the specification of the endoderm-derived organs, like thyroid and pancreas. Of 
note, no glis3 expression is observed in the differentiated thyroid at 2dpf [97].  
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In adults, glis3 is still present in pancreas, kidney, and pituitary, and at low levels in 
brain and gonads, suggesting a post-natal activity in the regulation of some organ 
functions. Given the lack of a compact thyroid gland in adult zebrafish, it was not 
possible to dissect the single follicles for the analysis. However, further experiments are 
needed to get though this limitation.    
To gain insights into glis3 function, we analysed the progression of embryonic thyroid 
development after the knockdown of glis3 mRNA expression using specific antisense 
morpholino oligonucleotide. 
At 1dpf, when the thyroid precursors arise from the pharyngeal floor of the endoderm, 
the glis3 morphants displayed a significant reduction or absent expression of the 
transcription factors nkx2.4 and pax2a in the thyroid primordium. At this point, we 
wondered if the thyroid phenotype associated with glis3 KD results from an increased 
apoptosis or decreased proliferations of thyroid precursors, as well as from a global 
alteration of the endoderm. Since no changes in proliferation/apoptosis rates and in 
foxa2 expression were detected in glis3 morphants when compared with controls, we 
can conclude that glis3 is early involved in endoderm specification, likely regulating the 
number of endodermal cells committed to thyroid fate. These data are in contrast with 
what seen during the early phases of thyroid development that appeared almost 
uneventful in Glis3-KO mice, but are consistent with the previously demonstrated bi-
modal action of GLIS3 during pancreatic development and function and with the 
thyroid morphogenetic defect seen in patients with homozygous mutations and 
complete GLIS3 loss-of-function.  
We also detected a defective amount of thyroid precursors at later stages, in which the 
expression of tg and slc5a5 is reduced or absent in most of the analysed embryos. The 
role of Glis3 in controlling Slc5a5 expression was previously reported in mice. RNA-
seq and CHIP-seq analyses of mice thyroid tissue confirm that Glis3 interacts and 
enhance the expression of Nis, directly regulating the synthesis of TH. In fact, Nis is 
suppressed in the thyroid gland of the Glis3-KO mice [79]. The specificity of the 
defects in thyroid development observed in morphants is also confirmed by the rescue 
experiment. The co-injection of the wild type form of the zebrafish glis3 mRNA and the 
glis3MO_SPL is able to restore the proper thyroid specification and normalizes the 
expression of both early and late thyroid markers. More interestingly, the 
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overexpression of the glis3 mRNA is sufficient to increase the number of the thyroid 
precursors at 1dpf, thus leading to the differentiation of a larger thyroid tissue and an 
elevation of T4 levels at later stages.  
Taken together, we propose glis3 as a key regulator of thyroid development and, in 
particular, in the specification of thyroid precursor cells, acting upstream the 
transcription factors nkx2.4 and pax2a. The defective thyroid tissue associated with low 
T4 synthesis and the high tshba levels observed in glis3 knockdown embryos resemble 
the biochemical features and thyroid dysgenesis reported in patients carrying biallelic 
mutations leading to a complete GLIS3 loss-of-function. Interestingly and consistently 
with our proposal of an early action of GLIS3 during thyroid specification, another 
group previously reported the existence of GLIS3-binding-sites in PAX8 promoter (10). 
The molecular mechanisms involved in Glis3 action have been extensively investigated 
during pancreas development, to gain insight into its role in diabetes. Three groups 
independently generated Glis3-deficient mice models and identified Ngn3, Insulin and 
Ccnd2 as direct downstream targets of Glis3 in the pancreatic progenitors and β-cells 
[74, 82, 84, 101]. The Glis3-/- mice display decreased expression of Ngn3 in the 
embryonic pancreas resulting in reduced differentiation of β-cells and severe 
hyperglycaemia and ketoacidosis in littermates [74, 83]. In vitro experiments 
demonstrate that Glis3 binds the endocrine lineage-defining transcription factors Hnf6 
and Foxa2 and the promoter/enhancer of Ngn3, synergistically transactivating its 
transcription [83].  
Given the Glis3 dual role in pancreas organogenesis and in regulation of insulin 
secretion and sensitivity, we propose the conservation of these two distinct 
physiological mechanisms also in thyroid. In fact, our zebrafish model supports the 
early involvement of glis3 during the specification of thyroid precursor, whereas the 
murine KO model [79] recapitulate the involvement of Glis3 controlling the TH 
synthesis and follicle proliferation in response to HPT-axis activation.  
In the last decade most of the thyroid research is engaged in the identification of those 
signals that induced the endodermal cells to a thyroid fate. Recently, Antonica et al., for 
the first time, generate a functional thyroid from embryonic stem cells [102]. In this 
work it has been demonstrated that, in presence of doxycycline (Dox) and rhTSH in the 
medium, the overexpression of the transcription factors NKX2.1 and PAX8 is sufficient 
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to differentiate mouse embryonic stem cells (mESC) into thyroid follicular cells which 
organized in a functioning follicle structure. Importantly, when these follicles are 
grafted into athyreoid mice they are able to recovery thyroid hormone plasma levels 
[102]. Conversely, the mice transplanted with cells differentiated without Dox and 
rhTSH treatment remained hypothyroid, highlighting the need for more information 
regarding the signals that are required for the correct differentiation of thyroid 
precursors [102]. 
As far as we know, the Notch, Shh, and Bmp/Fgf pathways are reported to be involved 
in the commitment of the endocrine precursors [34, 45, 47, 49, 52, 54]. The SHH 
pathway is known to be a regulator of the endoderm specification and thyroid 
development [54]. In our work, we investigate, for the first time, the role of the glis3-
shh pathway during the development of thyroid primordium. Our data strongly suggest 
that glis3 acts within the Shh pathway during this early developmental window.  
We observed that the expression of the shha in glis3 morphants is significantly reduced 
in the pharyngeal endoderm. When we blocked the Shh signalling, by injection of a 
specific shha morpholino or by treatment with the Shh-antagonist Cyclopamine, we 
detected an absent glis3 expression in the pharyngeal endoderm, pointing to a potential 
cross-talk mechanism between glis3 and Shh pathway in the endoderm. In addition, in 
Cyclopamine-treated embryos, we observed a lack of thyroid primordium as shown by 
the absent expression of both nkx2.4 and pax2a at 1dpf. At 2 and 3dpf, the tg-expressing 
follicles are also strongly reduced or absent in the treated embryos, confirming that 
glis3 acts downstream the Shh pathway during thyroid development.  
Interestingly, the overexpression of glis3 mRNA in Cyclopamine-treated embryos (in 
which Shh pathway is off) fails to rescue these thyroid defects, suggesting that glis3 
may require an active Shh signals for its transactivation activity.  
Although the specific molecular mechanisms are far from being understood, by 
similarity with the GLI-proteins, GLIS3 may act downstream the SHH signals, 
controlling the expression of several targets, like the Ins2 gene. It has been 
demonstrated that the binding of GLIS3 with the Suppressor of Fused (SUFU), a 
negative regulator of SHH signalling, is important for GLIS3 stability and activity [71]. 
In the absence of SHH, SUFU anchors GLIS3 in the cytoplasm and prevents its 
interaction with the ubiquitin ligase CUL3 and ITCH, thus protecting GLIS3 from 
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proteasome degradation [69]. The GLIS3-SUFU complex is also able to translocate into 
the nucleus, where it suppress the transcription of some target genes, such as Ins2. 
Conversely, when SHH is on, GLIS3 are released and forms a nuclear complex with 
coactivators, inducing the expression of Ins2 [67].  
Our preliminary data obtained in vitro by immunocytochemistry revealed that, like 
mice, the zebrafish sufu and glis3 proteins co-localized into the nucleus of the 
transfected cells. Hence, we can speculate that similarly to those observed with the 
insulin gene, glis3 through the interaction (direct or indirect) with sufu, is involved in 
the activation of specific early thyroid genes. In our proposed model, in the absence of 
the Shh signal, glis3 is maintained inactive by the binding with co-repressors, such as 
sufu. This complex represses the transcription of the early thyroid genes, maintaining 
the endodermal cell in the undifferentiated state (Figure 32A). In the presence of Shh, 
the sufu localization is restricted to the cytoplasm, and glis3 is able to translocate into 
the nucleus and forms a multi-protein complex that activates the transcription of target 
genes, like nkx2.4 and pax2a. As result through the activation of Shh-glis3 signal the 
undifferentiated endodermal cell is committed to the thyroid fate (Figure 32B).   
 
 In the last part of this work, we wondered if Shh-glis3 signalling interacts with other 
pathways, such as Notch/Jag1 and Hippo/Wwtr1 during zebrafish thyroid development. 
Notch is a highly conserved, local cell-signalling mechanism that participates in a 
variety of cellular processes and is involved in many aspects of development and 
disease. Several findings demonstrate that also the Notch signalling is important for the 
correct thyroid specification [47]. In fact, perturbations of the Notch signalling are 
associated with increased (Notch silencing) or diminished (Notch over-activation) 
number of thyroid precursors committed to the thyroid fate [49]. Furthermore, the 
knockdown of both ligands of the notch receptor, jag1a and jag1b, leads to thyroid 
hypoplasia and TSH elevated levels in zebrafish embryos [47].  
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Figure 32. Proposed mechanism of glis3-SHH signaling during zebrafish thyroid development.  In 
the right part of the figure we described the different phases of the thyroid development. The genetic 
markers involved in each step are reported. In the left box we illustrate the activity of glis3 in the 
presence or absence of Shh signal. (A) Undifferentiated endodermal cell in which Shh is off and glis3 is 
maintained inactive by sufu. (B) Differentiated thyroid precursor cell in which Shh is on, sufu is blocked 
by smo and glis3 form a transcriptional complex that induce the expression of the early thyroid genes.   
 
 
Regarding the Hippo pathway, it has been described that the transcriptional co-activator 
TAZ, also referred as Wwtr1, acts during the thyroid development [69, 75]. The Hippo 
pathway plays a role in the regulation of many biological functions, including cell 
migration, differentiation, proliferation, and cell polarity. In vitro experiments 
demonstrate that Wwtr1 is able to bind the C-terminus of Glis3 and function as co-
activator of Glis3 activity [61, 74]. In zebrafish wwtr1 gene is expressed in thyroid 
primordium; the analysis of the wwtr1 morphants reveal significant reduction of the 
number of thyroid follicle cells and also the lumen of follicles appear smaller compared 
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to control embryos [90]. It is also known that Wwtr1 is a potent regulator of Pax8 and 
Nkx2.1 controlling the thyroid gland development and differentiation [99]. Furthermore, 
it has been described that wwtr1 interacts with the Notch signalling for the regulation of 
cell-fate decision during zebrafish kidney development [100]. 
Our results exclude a direct interaction and the mutual regulation between Shh-glis3 and 
Notch and Hippo pathways.  
 
In conclusion, we demonstrate the key role of glis3 during the zebrafish thyroid 
development. The whole of these data suggests Glis3 as an element, acting within the 
Shh pathway, that is required for the thyroid commitment of the endoderm precursors 
through a direct or indirect regulation of the expression of specific transcription factors, 
such as nkx2.1, pax2a (Figure 32). 
Since biallelic GLIS3 mutations are associated with thyroid dysgenesis, we believe 
these data contribute to increase our understanding on the genetic bases of CH in 
humans. 
However the limitation of the morpholino injection hampers us to follow the 
progression of the CH. For that reason, we are now generating a stable glis3 mutant line 
using the CRISPR/Cas9 technology. The availability of juvenile and adult mutants will 
let a deep comprehension of the glis3 contribution to the thyroid hormone synthesis and 
the follicle proliferation in response to activation of the HPT-axis. Finally, this mutant 
model will be suitable for a high-throughput drug-screening, providing a new potential 
therapeutical approach, for NDH and CH pathologies.  
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